[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 136
1. van den Top JG, de Heer N, Klein WR, Ensink JM: Penile and preputial tumours in the horse: a retrospective study of 114 affected horses. Equine Vet J; 2008 Sep;40(6):528-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data recorded included age, gelding or stallion and breed; type and site of lesion; involvement of regional lymph nodes; histopathology (including grading of squamous cell carcinoma); and results of radiographic examination of the thorax.
  • Squamous cell carcinoma (SCC) was the most prevalent neoplasm followed by papillomas and melanomas.
  • A basal cell carcinoma, neurofibrosarcoma, adenocarcinoma or fibrosarcoma were each found on single horses.
  • Squamous cell carcinomas with poor differentiation had a higher tendency to metastasise than did more differentiated tumours.
  • CONCLUSIONS: Squamous cell carcinoma is the most common urogenital tumour of the male horse and occurs primarily in old horses.
  • [MeSH-major] Carcinoma, Squamous Cell / veterinary. Horse Diseases / pathology. Penile Neoplasms / veterinary
  • [MeSH-minor] Age Factors. Animals. Breeding. Horses. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis / diagnosis. Male. Neoplasm Metastasis / diagnosis. Neoplasm Staging / veterinary. Orchiectomy / veterinary. Papilloma / epidemiology. Papilloma / pathology. Papilloma / surgery. Papilloma / veterinary. Pedigree. Penis / pathology. Penis / surgery. Retrospective Studies. Urethra / pathology. Urethra / surgery

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487101.001).
  • [ISSN] 0425-1644
  • [Journal-full-title] Equine veterinary journal
  • [ISO-abbreviation] Equine Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Wang Y, Li Y, Zhang WY, Xia QJ, Li HG, Wang R, Yang L, Sun XF, Zhou ZG: mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma. Eur J Cancer Prev; 2009 Feb;18(1):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma.
  • Here, we aimed to evaluate the possible value of a proliferation marker, minichromosome maintenance 2 (MCM2), in the early diagnosis of colorectal cancer, by analyzing the difference in MCM2 expression among normal mucosa, adenoma, and adenocarcinoma, and investigating the relationship of MCM2 expression in adenomas with clinicopathologic variables.
  • Using immunohistochemistry and real-time reverse transcription-PCR, we observed that the expression of MCM2 protein was present on basal third to half of colonic crypts in normal mucosa, whereas throughout the epithelium in adenomas and adenocarcinomas, the expression of MCM2 mRNA in adenocarcinomas was significantly higher than in adenomas (P=0.001), whereas the difference between adenoma and normal mucosa was not significant (P=0.184); we also found that the expression of MCM2 mRNA tended to be increased in the adenomas with high-grade dysplasia, or in older patients, respectively, compared with those with low-grade dysplasia, and younger patients.
  • These results suggested the potential value of MCM2 in early diagnosis of colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Cell Cycle Proteins / genetics. Colonic Neoplasms / genetics. Nuclear Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077563.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


3. Luebke AM, Schlomm T, Gunawan B, Bonkhoff H, Füzesi L, Erbersdobler A: Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach. Virchows Arch; 2005 Mar;446(3):338-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach.
  • Basal cell tumours of the prostatic gland are rare, and the classification is difficult.
  • In the present case report, a large, tumour-like proliferation of atypical basaloid cells was found incidentally in a prostatectomy specimen that otherwise contained a conventional acinar adenocarcinoma.
  • A high Ki-67 index was recorded within the atypical basaloid cells, by far exceeding the one counted in the conventional adenocarcinoma.
  • However, there were no definite criteria for a malignant behaviour of the basal cell tumour.
  • Comparative genomic hybridisation from microdissected tumour cells yielded losses at the short arms of chromosomes 8 and 12 in the conventional adenocarcinoma and a normal karyotype in the basal cell tumour.
  • The pathological findings favoured the diagnosis of an atypical basal cell hyperplasia.
  • [MeSH-major] Carcinoma, Acinar Cell / complications. Carcinoma, Acinar Cell / pathology. Prostatic Hyperplasia / complications. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / complications. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasms, Basal Cell / genetics. Neoplasms, Basal Cell / pathology. Nucleic Acid Hybridization

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1993 Aug;117(8):799-801 [8343043.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):342-7 [7529134.001]
  • [Cites] Eur Urol. 1999;36(1):21-30 [10364651.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):668-72 [14999772.001]
  • [Cites] Histopathology. 1992 Feb;20(2):151-5 [1559669.001]
  • [Cites] Pathol Res Pract. 1990 Feb;186(1):28-36 [2179908.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):645-59 [7686348.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):231-43 [7522536.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):202-8 [11161378.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):612-29 [9195581.001]
  • [Cites] Virchows Arch. 2003 Dec;443(6):787-91 [14756145.001]
  • [Cites] Hum Pathol. 1988 Dec;19(12):1425-33 [2461340.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1523-9 [14657711.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):399-406 [11159178.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):43-51 [12107088.001]
  • [Cites] Am J Surg Pathol. 1992 Dec;16(12):1205-14 [1281386.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1225-33 [2400973.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1447-50 [9865831.001]
  • (PMID = 15726402.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


Advertisement
4. Leite KR, Srougi M, Sanudo A, Dall'oglio MF, Nesrallah A, Antunes AA, Cury J, Camara-Lopes LH: The use of immunohistochemistry for diagnosis of prostate cancer. Int Braz J Urol; 2010 Sep-Oct;36(5):583-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of immunohistochemistry for diagnosis of prostate cancer.
  • The use of antibodies to mark basal cells is currently a common practice, in order to avoid rebiopsies.
  • There has been no reported study that has reviewed characteristics of radical prostatectomies (RPs) when immunohistochemistry (IHC) was necessary for definitive diagnosis.
  • The results of surgical specimens of 27 patients treated by RP after the diagnosis of prostate cancer (PC) was made using IHC (Group 1) were compared with 1040 patients where IHC was not necessary (Group 2).
  • In Group 1, two (7.4%) adenocarcinomas were insignificant versus 29 (2.9%) for Group 2.
  • CONCLUSION: The use of IHC did not lead to diagnosis of insignificant tumors as illustrated by absence of differences in pathological stage or positive surgical margins in men submitted to RP.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Cell Proliferation. Humans. Immunohistochemistry / methods. Male. Middle Aged

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21044375.001).
  • [ISSN] 1677-6119
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


5. Lakhtakia R, Bharadwaj R, Kumar VK, Mandal P, Nema SK: Immunophenotypic Characterization of Benign and Malignant Prostatic Lesions. Med J Armed Forces India; 2007 Jul;63(3):243-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Biopsy diagnosis is the gold standard for differentiating benign and malignant prostatic enlargements.
  • This study was aimed at supplementing biopsy diagnosis with immunophenotypic characters of prostatic lesions.
  • METHODS: Twenty five cases each of nodular hyperplasia and adenocarcinoma prostate were compared for their morphologic appearances and immunophenotyping, by studying antibodies to prostate specific antigen (PSA), transglutaminase, chromogranin and high molecular weight keratin, proliferating cell nuclear antigen, cell death (apoptosis) and neovascularisation (CD 34).
  • Loss of basal cells around malignant prostatic acini as determined by high molecular weight keratin (HMWK), was useful in foci of atypical small acinar proliferation and in prostatic intraepithelial neoplasia.
  • Assessment of proliferation indices identified subsets of tumours, within conventional morphologic Gleason's grades, with a higher growth fraction.
  • Cell death determination and study of tumour vessels did not offer any improvement on morphology.
  • CONCLUSION: Immunophenotypic assessment helps in refining morphologic diagnosis of prostatic lesions.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27408008.001).
  • [ISSN] 0377-1237
  • [Journal-full-title] Medical journal, Armed Forces India
  • [ISO-abbreviation] Med J Armed Forces India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC4922757
  • [Keywords] NOTNLM ; Benign / Immunophenotyping / Malignant / Prostate
  •  go-up   go-down


6. Adamski H, Le Lan J, Chevrier S, Cribier B, Watier E, Chevrant-Breton J: Primary cutaneous cribriform carcinoma: a rare apocrine tumour. J Cutan Pathol; 2005 Sep;32(8):577-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histopathological diagnosis is difficult, mainly because this tumour is exceptional.
  • Differential diagnoses, including cutaneous metastasis of adenocarcinoma, adenoid basal cell carcinoma and adenoid cystic carcinoma, are discussed.
  • [MeSH-major] Adenocarcinoma / pathology. Apocrine Glands / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115058.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


7. Lovrić E, Gatalica Z, Eyzaguirre E, Kruslin B: Expression of maspin and glutathionine-S-transferase-pi in normal human prostate and prostatic carcinomas. Appl Immunohistochem Mol Morphol; 2010 Oct;18(5):429-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Maspin and GST-pi were strongly and consistently coexpressed in the cytoplasm of basal cells of normal prostatic glands, whereas normal luminal cells were inconsistently weakly positive.
  • Prostatic adenocarcinomas overexpressed maspin in 27/34 cases (79%).
  • CONCLUSION: Consistent coexpression of maspin and GST-pi was observed in basal cells of the prostatic glands, which could be used as an additional immunohistochemical test in the evaluation of prostatic malignancy.
  • Prostatic adenocarcinomas express maspin in an aberrant nuclear distribution without coexpresion of GST-pi.
  • These results indicate a deregulation of expression of maspin and GST-pi in prostatic adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20453817.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


8. Saad RS, Liu YL, Silverman JF: Distribution of basal/myoepithelial markers in benign and malignant bronchioloalveolar proliferations of the lung. Appl Immunohistochem Mol Morphol; 2010 May;18(3):219-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of basal/myoepithelial markers in benign and malignant bronchioloalveolar proliferations of the lung.
  • We investigated the staining pattern of commonly used basal cell/myoepithelial markers, such as p63 (a p53-homologous nuclear protein), basal cell-specific cytokeratin antibody (34betaE12, K903), and smooth muscle myosin heavy chain (SMMHC) in benign and malignant bronchioloalveolar proliferations of the lung.
  • We studied 85 lung lesions consisting of 35 bronchioloalveolar carcinoma, 30 well-differentiated adenocarcinoma, and 20 cases of benign lung lesions.
  • In normal lung, p63, K903, and SMMHC decorated the basal cells of large and small airways and occasional cells of terminal bronchioles.
  • In reactive processes, a distinctive staining pattern was present in 19/20 (95%) of the cases characterized by staining of basal cells of the airways and bronchiolar epithelium and squamous metaplastic epithelium for p63 and K903, whereas 12/20 (60%) stained with SMMHC.
  • For adenocarcinoma, a majority of the cases (28/30, 93%) were negative for p63 and K903; however, SMMHC showed artifactual staining in the desmoplastic stroma in 6/30 (20%) cases.
  • Our results highlighted the differential expression of basal cell markers across various bronchioloalveolar lesions.
  • The staining pattern of basal cells in bronchioloalveolar carcinoma supports that these neoplasms may actually be carcinoma in-situ.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065853.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins; EC 3.6.1.- / Smooth Muscle Myosins
  •  go-up   go-down


9. Wang Y, Zhou ZG, Xia QJ, Zhang WY, Li HG, Wang R: [Expression of minichromosome maintenance protein 2 in colonic adenocarcinoma, adenoma and normal colonic mucosa and its clinical significance]. Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Sep;11(5):465-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of minichromosome maintenance protein 2 in colonic adenocarcinoma, adenoma and normal colonic mucosa and its clinical significance].
  • OBJECTIVE: To investigate the expression differences of minichromosome maintenance 2 (MCM2) mRNA and protein among colon adenocarcinoma, colon adenoma and normal mucosa, and among different clinicopathological types of adenomas.
  • METHODS: Fifty specimens, including 33 colonic adenomas, 12 colonic adenocarcinomas and 5 normal colonic mucosa were selected.
  • Expression differences of MCM2 mRNA among the colonic adenocarcinoma, adenoma and normal colonic mucosa were evaluated by REST-XL software.
  • RESULTS: The expression of MCM2 was observed in the basal third to half of the colonic crypts in normal mucosa, while throughout the epithelium in the colonic adenocarcinomas and adenomas.
  • However, the expression of MCM2 mRNA in the adenocarcinomas was significantly higher than that in the adenomas(P=0.001).
  • CONCLUSION: The difference of MCM2 expression between the adenoma and the adenocarcinoma indicates its potential value in the early diagnosis of colonic cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Cell Cycle Proteins / metabolism. Colonic Neoplasms / metabolism. Nuclear Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803052.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


10. Adley BP, Yang XJ: Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review. Anal Quant Cytol Histol; 2006 Feb;28(1):1-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review.
  • Alpha-methylacyl coenzyme A racemase (AMACR) is a recently discovered enzyme protein that has been shown to be increased at both the mRNA and protein levels in prostatic adenocarcinoma as compared with normal prostatic tissues.
  • Since its discovery, AMACR has gained wide acceptance for use in the diagnosis of prostatic adenocarcinoma in conjunction with morphology and immunohistochemical staining for basal cell markers.
  • This review focuses on AMACR expression in prostate cancer and its morphologic variants, high grade prostatic intraepithelial neoplasia, adenosis and benign conditions of the prostate.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566275.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Number-of-references] 63
  •  go-up   go-down


11. Kazakov DV, Benkova K, Michal M, Vanecek T, Kacerovska D, Skalova A: Skin type spiradenoma of the parotid gland with malignant transformation: report of a case with analysis of the CYLD gene. Hum Pathol; 2009 Oct;40(10):1499-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A distinctive variant of basal cell adenoma called membranous basal cell adenoma is well recognized in salivary glands.
  • In addition, the lesion had a malignant component identical to basal cell adenocarcinoma.
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. DNA Mutational Analysis. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454360.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


12. Habermann CR, Arndt C, Graessner J, Diestel L, Petersen KU, Reitmeier F, Ussmueller JO, Adam G, Jaehne M: Diffusion-weighted echo-planar MR imaging of primary parotid gland tumors: is a prediction of different histologic subtypes possible? AJNR Am J Neuroradiol; 2009 Mar;30(3):591-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic diagnosis was obtained in every patient.
  • Mucoepidermoid carcinomas, acinic cell carcinomas, and basal cell adenocarcinomas were not differentiable from Warthin tumors (P = .094, .396, and .604, respectively).
  • Therefore, further studies combining DWI, morphologic criteria, and probably other MR imaging techniques seem warranted.
  • [MeSH-minor] Adenolymphoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / pathology. Carcinoma, Mucoepidermoid / pathology. Diagnosis, Differential. Female. Humans. Lipoma / pathology. Male. Middle Aged. Prospective Studies. Salivary Gland Neoplasms / pathology. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131405.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Ward BK, Seethala RR, Barnes EL, Lai SY: Basal cell adenocarcinoma of a hard palate minor salivary gland: case report and review of the literature. Head Neck Oncol; 2009 Dec 23;1:41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of a hard palate minor salivary gland: case report and review of the literature.
  • OBJECTIVE: Basal cell adenocarcinoma of a minor salivary gland is extremely rare.
  • The goal of this report is to increase awareness of this rare disease and to review and discuss the differential diagnosis and important considerations in treatment.
  • METHODS: Case report of a basal cell adenocarcinoma of a hard palate minor salivary gland and review of the literature of basal cell adenocarcinoma.
  • RESULTS: Basal cell adenocarcinomas are slow-growing tumours that most commonly involve the parotid gland and very rarely involve minor salivary glands.
  • Histological diagnosis is important to distinguish this tumour from adenoid cystic carcinoma given the significant difference in disease prognosis.
  • CONCLUSIONS: Diagnosis of these tumours must be made histologically.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol. 1978 Feb;104(2):111-6 [629699.001]
  • [Cites] J Oral Pathol. 1985 Jul;14(6):500-9 [2991488.001]
  • [Cites] Arch Pathol Lab Med. 1988 Feb;112(2):209-11 [2827601.001]
  • [Cites] J Laryngol Otol. 1989 Aug;103(8):756-9 [2769045.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Apr;69(4):461-9 [2326038.001]
  • [Cites] Cancer. 1996 Dec 15;78(12):2471-7 [8952553.001]
  • [Cites] Oral Oncol. 2008 Apr;44(4):407-17 [17825603.001]
  • [Cites] HNO. 1998 Sep;46(9):821-5 [9816537.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jul;34(5):528-32 [16053873.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Feb;35(2):150-4 [16181771.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 Mar;11(2):E206-9 [16505803.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jan;103(1):77-84 [17178498.001]
  • [Cites] J Oral Pathol Med. 2007 Apr;36(4):207-14 [17391298.001]
  • [Cites] Acta Otolaryngol. 1998 Jul;118(4):588-93 [9726688.001]
  • (PMID = 20030819.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / K08 DE018061
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806868
  • [General-notes] NLM/ Original DateCompleted: 20100629
  •  go-up   go-down


14. González-García R, Nam-Cha SH, Muñoz-Guerra MF, Gamallo-Amat C: Basal cell adenoma of the parotid gland. Case report and review of the literature. Med Oral Patol Oral Cir Bucal; 2006 Mar;11(2):E206-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the parotid gland. Case report and review of the literature.
  • Basal cell adenoma of the salivary glands is an uncommon type of monomorphous adenoma.
  • Histologically, isomorphic cells in nests and interlaced trabecules with a prominent basal membrane are observed.
  • Due to prognostic implications, differential diagnosis with basal cell adenocarcinoma, adenoid cystic carcinoma and basaloid squamous cell carcinoma is mandatory.
  • We describe a case of basal cell adenoma of the parotid gland.
  • We also review the literature and discuss the diagnosis and management of this rare entity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16505803.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 21
  •  go-up   go-down


15. Shah RB, Magi-Galluzzi C, Han B, Zhou M: Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies. Am J Surg Pathol; 2010 Apr;34(4):470-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies.
  • Atypical cribriform lesions of the prostate (ACL) are cribriform glands lined by cytologically malignant cells with partial or complete basal cell lining.
  • We report the incidence, topographic relation to cancer, and morphologic differences of these 2 lesions in radical prostatectomy and discuss the potential biologic basis and implication for diagnosis in prostate biopsy.
  • ACL was defined as cribriform glands comprising cytologically malignant cells that spanned the entire glandular lumens with partial or complete basal cell lining confirmed by basal cell immunostaining.
  • However, cribriform HGPIN and IDC-P overlap at the "low grade" architectural and morphologic spectrum and are difficult to distinguish based on morphologic criteria alone.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20182345.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kong CS, Beck AH, Longacre TA: A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas. Am J Surg Pathol; 2010 Jul;34(7):915-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.
  • Endometrial and endocervical adenocarcinomas may seem histologically identical and it can be difficult to determine primary site of origin based on morphology alone.
  • The TMA consisted of 214 endometrial carcinomas, 33 endocervical adenocarcinomas, and 36 problematic cases.
  • The endometrial and endocervical carcinomas represented usual endometrioid and mucinous types, and special variants (uterine serous carcinoma, uterine clear cell carcinoma, minimal deviation endocervical adenocarcinoma, cervical small cell carcinoma, adenoid basal cell carcinoma, mesonephric carcinoma).
  • Using a script written in R, the diagnostic accuracy of all possible combinations of markers was evaluated and it was shown that a 3 marker panel including vimentin, ER, or PR, and an HPV marker (p16, ProExC, or HPV ISH) is optimal for determining site of origin for usual endometrial and endocervical adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. DNA, Viral / analysis. Endometrial Neoplasms / diagnosis. Papillomaviridae / genetics. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Papillomavirus Infections / diagnosis. Reproducibility of Results. Tissue Array Analysis. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534993.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NLM NIH HHS / LM / T15 LM007033
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / Vimentin
  • [Other-IDs] NLM/ NIHMS775595; NLM/ PMC4847142
  •  go-up   go-down


17. Toida M, Shimokawa K, Makita H, Kato K, Kobayashi A, Kusunoki Y, Hatakeyama D, Fujitsuka H, Yamashita T, Shibata T: Intraoral minor salivary gland tumors: a clinicopathological study of 82 cases. Int J Oral Maxillofac Surg; 2005 Jul;34(5):528-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, the tumors were classified as pleomorphic adenoma (n = 54), papillary cystadenoma (n = 1), adenoid cystic carcinoma (n = 10), mucoepidermoid carcinoma (n = 8), acinic cell carcinoma (n = 3), adenocarcinoma (n = 2), basal cell adenocarcinoma (n = 1), papillary cystadenocarcinoma (n = 1), and carcinoma in pleomorphic adenoma (n = 2).
  • From the results of the present study and review of the literature, it is suggested that the minor salivary gland tumors in Japan may be characterized by a higher incidence of benign tumors, especially of pleomorphic adenoma; a more marked tendency for female predominance; a higher incidence of palatal involvement; and a rarer occurrence of polymorphous low grade adenocarcinoma, in comparison with those reported in the literature from outside of Japan.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenoma, Pleomorphic / epidemiology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / epidemiology. Carcinoma, Mucoepidermoid / epidemiology. Cheek / pathology. Child. Female. Humans. Japan / epidemiology. Lip / pathology. Male. Middle Aged. Palate / pathology. Retrospective Studies. Sex Factors

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16053873.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


18. Went PT, Sauter G, Oberholzer M, Bubendorf L: Abundant expression of AMACR in many distinct tumour types. Pathology; 2006 Oct;38(5):426-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Alpha-methylacyl-CoA racemase (AMACR), a mitochondrial and peroxisomal enzyme, is a valuable tool to confirm the diagnosis of prostate cancer, especially if combined with basal cell markers.
  • RESULTS: Microarray analysis revealed that tumours with prominent AMACR expression included adenocarcinomas of the prostate (72%), hepatocellular carcinomas (77%), papillary renal cell carcinomas (70%), and colorectal adenocarcinomas (71%).
  • CONCLUSION: Taken together, the results indicate that AMACR is expressed in a wide variety of adenocarcinomas, and its diagnostic utility is restricted to specific areas.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism. Racemases and Epimerases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17008281.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


19. Wietfeldt ED, Thiele J: Malignancies of the anal margin and perianal skin. Clin Colon Rectal Surg; 2009 May;22(2):127-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Commonly included in this group of cancers are Bowen's disease (intraepithelial squamous cell cancer), perianal Paget's disease (intraepithelial adenocarcinoma), invasive squamous cell cancer, basal cell cancer, and malignant melanoma.
  • Proper diagnosis requires a high index of suspicion on the part of the surgeon.
  • Innocent local irritations will resolve in a short time with appropriate therapy; those that persist must be biopsied for tissue diagnosis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2008 Dec;51(12):1842-5 [18584248.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):11-21 [17199561.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):587-90 [11442599.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]
  • [Cites] Br J Dermatol. 1995 Jun;132(6):970-2 [7662577.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • (PMID = 20436838.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780245
  • [Keywords] NOTNLM ; Anal margin cancer / diagnosis / local excision / radiation therapy / treatment options
  •  go-up   go-down


20. Lal DR, Clark I, Shalkow J, Downey RJ, Shorter NA, Klimstra DS, La Quaglia MP: Primary epithelial lung malignancies in the pediatric population. Pediatr Blood Cancer; 2005 Oct 15;45(5):683-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reviewed the Memorial Sloan-Kettering Cancer Center experience with these tumors to better understand their histology, time to diagnosis, treatment, and outcome.
  • PROCEDURE: A retrospective review was performed on all patients 21 years of age or younger at diagnosis, treated for primary epithelial lung malignancies at Memorial Sloan-Kettering Cancer Center between 1980 and 2001.
  • The median age at diagnosis was 19 (range: 12-21) years.
  • The most common radiographic abnormality was a mass (55%) on chest imaging.
  • Seven patients (64%) were initially diagnosed as having pneumonia which contributed to a delay in diagnosis.
  • Final pathologic diagnoses included adenocarcinoma (four), carcinoid tumor (three typical, one atypical), basaloid carcinoma (two), and mucoepidermoid carcinoma (one).
  • CONCLUSIONS: When children and adolescents present with primary epithelial lung malignancy a majority will have advanced disease and experience a delay in diagnosis.
  • Patients with carcinoid tumors seem to have the best prognosis, followed by adenocarcinoma.
  • [MeSH-major] Carcinoma / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adolescent. Adult. Carcinoid Tumor / diagnosis. Carcinoid Tumor / pathology. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Child. Diagnostic Errors. Female. Humans. Male. Pneumonia / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714450.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Xue LY, Zou SM, Zheng S, Xie YQ, Wen P, Liu XY, Lin DM, Lü N: [Expression of fascin and CK14 in different histological types of cancer and its differential diagnostic significance]. Zhonghua Zhong Liu Za Zhi; 2010 Nov;32(11):838-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate and analyze the expression of fascin and CK14 in multiple histological types of cancer and to explore the potential value of the two proteins as markers in diagnosis and differential diagnosis of various cancer types.
  • METHODS: Tissue microarray containing esophageal squamous cell carcinoma (SCC), lung SCC, larynx SCC, uterine cervical SCC, SCC of external genital organs, lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, heptocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating ductal carcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma and renal clear cell carcinoma, 30 cases each, as well as corresponding normal controls was constructed.
  • RESULTS: In normal esophagus, bronchus, larynx, uterine cervix and skin, fascin was mainly expressed in the basal cells or reserve cells, but the expression was diffuse in esophageal SCC, lung SCC, larynx SCC, uterine cervical SCC and SCC of external genital organs, with a positive rate of 90.0%, 90.0%, 96.7%, 78.6% and 89.7%, respectively.
  • In lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating dutal adenocarcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma and renal clear cell carcinoma, the positive rates were 38.0%, 23.3%, 14.3%, 10.3%, 73.3%, 13.3%, 6.7%, 60.0%, 66.7% and 10.0%, respectively.
  • CK14 was mainly expressed in the basal cells, reserve cells or myoepithelia of normal tissues.
  • It was weak and focal in lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating dutal adenocarcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma, and renal clear cell carcinoma, with a positive rate of 13.3%, 13.3%, 20.7%, 41.4%, 46.7%, 6.7%, 40.0%, 13.3%, 20.0% and 6.7%, respectively.
  • Combination of fascin and CK14 should be a valuable marker in diagnosis and differential diagnosis of carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Carrier Proteins / metabolism. Keratin-14 / metabolism. Laryngeal Neoplasms / metabolism. Microfilament Proteins / metabolism
  • [MeSH-minor] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Diagnosis, Differential. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / pathology. Female. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21223690.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Keratin-14; 0 / Microfilament Proteins; 146808-54-0 / fascin
  •  go-up   go-down


22. Kanitakis J, Chouvet B: Granular-cell basal cell carcinoma of the skin. Eur J Dermatol; 2005 Jul-Aug;15(4):301-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular-cell basal cell carcinoma of the skin.
  • Granular cell basal cell carcinoma (GBCC) is a very rare variant of BCC, of which ten cases have been reported in the literature.
  • [MeSH-major] Adenocarcinoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048765.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 12
  •  go-up   go-down


23. Akrish S, Peled M, Ben-Izhak O, Nagler RM: Malignant salivary gland tumors and cyclo-oxygenase-2: a histopathological and immunohistochemical analysis with implications on histogenesis. Oral Oncol; 2009 Dec;45(12):1044-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Strong cox-2 overexpression was noted in all MST of proposed excretory duct origin: salivary duct carcinoma (100%), mucoepidermoid carcinoma (MEC) (92%), and adenocarcinoma nos (AdC nos) (83%).
  • Primary squamous cell carcinoma (PSCC) was the exception.
  • Negative expression was noted in all tumors of proposed intercalated duct origin (adenoid cystic carcinoma, basal cell adenocarcinoma and acinic cell carcinoma) with the exception of one case of polymorphous low grade adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19729335.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


24. Zhou M, Magi-Galluzzi C, Epstein JI: Prostate basal cell lesions can be negative for basal cell keratins: a diagnostic pitfall. Anal Quant Cytol Histol; 2006 Jun;28(3):125-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate basal cell lesions can be negative for basal cell keratins: a diagnostic pitfall.
  • BACKGROUND: Prostate basal cell lesions can have architectural and cytologic atypia that mimic prostate adenocarcinoma.
  • Immunohistochemical stains for basal cell markers are most helpful in the differential diagnosis.
  • All of the published studies show basal cell lesions are positive for basal cell keratins, whereas adenocarcinoma is negative for both.
  • We reported two cases of prostate basal cell lesions with negative basal cell keratin expression by immunohistochemistry.
  • STUDY DESIGN: We reported the histologic and immunohistochemical profiles of two cases of basal cell lesions of the prostate.
  • RESULTS: Histologically, both cases were highly suspicious for prostate adenocarcinoma with infiltrative growth pattern and significant nuclear atypia.
  • The atypical glands in both cases were negative for basal cell keratins.
  • However, both lesions were positive for another basal cell marker, p63, confirming that they were basal cells in origin, rather than prostate adenocarcinoma.
  • CONCLUSION: Prostate basal cell lesions can occasionally be negative for basal cell keratins by immunohistochemistry and therefore may be misdiagnosed as prostate adenocarcinoma.
  • We recommend using both p63 and basal cell keratins simultaneously in the workup of atypical prostate lesions to avoid such a misdiagnosis.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786721.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


25. Baydar DE, Himmetoglu C: Test and Teach. Abnormal glands in the uterine cervix Part 1. Diagnosis: Ectopic prostate tissue in the uterine cervix. Pathology; 2008 Jun;40(4):407-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Test and Teach. Abnormal glands in the uterine cervix Part 1. Diagnosis: Ectopic prostate tissue in the uterine cervix.
  • [MeSH-minor] Acid Phosphatase. Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prostate-Specific Antigen / metabolism. Protein Tyrosine Phosphatases / metabolism. Uterine Cervical Neoplasms / diagnosis


26. Samaratunga H, Delahunt B: Ductal adenocarcinoma of the prostate: current opinion and controversies. Anal Quant Cytol Histol; 2008 Aug;30(4):237-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal adenocarcinoma of the prostate: current opinion and controversies.
  • OBJECTIVE: To evaluate the morphologic spectrum and clinical significance of ductal adenocarcinoma of the prostate (DAP).
  • STUDY DESIGN: We reviewed diagnostic criteria, including the value of immunohistochemistry, and outlined the prognostic implications of a diagnosis of DAP.
  • A basal cell layer can be seen in some of these tumors, which is probably due to tumor growth into preexisting ducts.
  • CONCLUSION: DAP are neoplasms of prostatic origin, and the terms endometrioid or endometrial adenocarcinoma are best avoided.
  • DAP are aggressive tumors with a shortened average time to progression compared with acinar adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773743.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


27. Yamagata K, Oka K, Yoshida H, Yanagawa T, Onizawa K, Yusa H, Ishikawa A, Okada N: Basal cell adenocarcinoma arising from the minor salivary gland in the soft palate: a case report. Pathol Res Pract; 2006;202(6):475-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma arising from the minor salivary gland in the soft palate: a case report.
  • Basal cell adenocarcinomas (BCACs) of the oral minor salivary gland are very rare neoplasms.
  • [MeSH-major] Adenocarcinoma / pathology. Palate, Soft / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16487667.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


28. Chen RJ, Xiao YQ: [Clinical and pathological analysis of 2734 cases of eyelid neoplasms]. Zhonghua Yan Ke Za Zhi; 2008 Feb;44(2):143-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The three leading malignant eyelid tumors were basal cell carcinoma, meibomian gland carcinoma and squamous cell carcinoma The mean ages of the occurrence of these three tumors were 64.16, 63.30 and 60.38 years old, respectively.
  • CONCLUSION: Pathologic classification of eyelid neoplasms is helpful for the pathological diagnosis and provides information for the diagnosis and treatment of these diseases.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18683700.001).
  • [ISSN] 0412-4081
  • [Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • [ISO-abbreviation] Zhonghua Yan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


29. Xu XL, Li B, Sun XL, Li LQ, Ren RJ, Gao F: [Clinical and pathological analysis of 2639 cases of eyelid tumors]. Zhonghua Yan Ke Za Zhi; 2008 Jan;44(1):38-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 5 leading eyelid malignant tumors were basal cell carcinoma, sebaceous gland carcinoma, lymphoma, squamous cell carcinoma and melanoma.
  • The mean age at diagnosis was 61 years for basal cell carcinoma and sebaceous gland carcinoma, 57 years and 52 years for squamous cell carcinoma and melanoma, respectively, and 48 years for lymphoma.
  • There was no significant sex predilection in basal cell carcinoma and sebaceous gland carcinoma.
  • Melanoma and lymphoma occurred more commonly in women, whereas squamous cell carcinoma occurred more commonly in men.
  • CONCLUSIONS: Basal cell carcinoma and sebaceous gland carcinoma were the most common malignant eyelid tumors, and lymphoma ranked third and had an increasing trend.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510241.001).
  • [ISSN] 0412-4081
  • [Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • [ISO-abbreviation] Zhonghua Yan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. Hameed O, Humphrey PA: Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol; 2005 Feb;22(1):88-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Basal cell markers, such as the 34betaE12 antibody and antibodies directed against cytokeratin 5 and 6 or p63, are very useful for demonstration of basal cells as their presence argues against a diagnosis of invasive prostatic carcinoma (PC).
  • However, several benign mimickers of PC, including atrophy, atypical adenomatous hyperplasia (AAH), nephrogenic adenoma, and mesonephric hyperplasia, can stain negatively with these markers, and thus, a negative basal cell marker immunostain alone does not exclude a diagnosis of benignancy.
  • Although there are examples in the literature of high grade PC that stain focally with some of the basal cell markers, these cases are usually readily diagnosed based on H&E appearances and are unlikely to be confused with these benign mimickers.
  • Alpha-methylacyl-coenzyme-A racemase (AMACR) is a sensitive marker of PC (except for a few uncommon variants: atrophic, foamy gland, and pseudohyperplastic variants), and its detection by immunohistochemical staining in atypical prostatic lesions can be very useful in confirming an impression of adenocarcinoma.
  • AMACR expression can also be identified in high grade prostatic intraepithelial neoplasia (PIN), prostatic atrophy, AAH, and benign prostatic glands, and accordingly, a diagnosis of PC should not be based solely on a positive AMACR immunostain, especially when the luminal staining is weak and/or noncircumferential.
  • The use of AMACR/basal cell antibody cocktails has been found to greatly facilitate the distinction between PC and its benign mimickers, especially when only limited tissue is available for staining.
  • Prostate specific antigen (PSA) and prostate specific acid phosphatase (PSAP) are both quite sensitive and fairly specific markers of PC (there are a few nonprostatic tumors that can express one or both), and are both very helpful in establishing or confirming the diagnosis of PC when the differential diagnosis includes other tumors that can involve the prostate such as urinary bladder urothelial carcinoma.
  • 34betaE12, p63, thrombomodulin, and uroplakin III are additional urothelial associated markers useful in this differential diagnosis.
  • CDX2 and villin are useful markers to diagnostically separate colonic adenocarcinoma from PC.
  • AMACR positivity and negative basal cell marker reactions are useful to confirm the presence of residual PC after hormonal or radiation therapy.
  • PSA and PSAP immunohistochemical stains are valuable in confirming metastatic carcinoma as being of prostatic origin and should always be utilized in the diagnostic evaluation of metastatic adenocarcinoma of unknown primary origin in males.
  • [MeSH-major] Carcinoma / diagnosis. Immunohistochemistry. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Humans. Leukemia / diagnosis. Lymphoma / diagnosis. Male. Neoplasm Metastasis. Sarcoma / diagnosis. Sensitivity and Specificity. Urinary Bladder Neoplasms / diagnosis


31. Plaza JA, Wakely PE Jr, Suster S: Lipoblastic nerve sheath tumors: report of a distinctive variant of neural soft tissue neoplasm with adipocytic differentiation. Am J Surg Pathol; 2006 Mar;30(3):337-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign nerve sheath tumors of soft tissue can occasionally adopt unusual or unfamiliar morphologic appearances that may introduce difficulties for diagnosis, such as multinucleation, bizarre nuclei, intranuclear vacuoles, and other degenerative changes.
  • Tumor cells adopting a signet-ring or lipoblast-like configuration, however, are mostly associated with epithelial malignancies, liposarcoma and melanoma, and have been only rarely observed in spindle cell tumors of soft tissue.
  • Four tumors predominantly showed features of schwannoma and one of neurofibroma; however, intimately admixed with the spindle cell population, there were also numerous scattered mature adipocytes as well as lipoblast-like cells displaying a signet-ring cell appearance.
  • The signet-ring cells contained large cytoplasmic lipid droplets that displaced the nuclei to the periphery, consistent with lipoblastic differentiation, whereas complex, interdigitating cytoplasmic processes covered by basal lamina material characteristic of nerve sheath differentiation could be identified in the spindle cells.
  • Neurogenic tumors should be added in the differential diagnosis of spindle cell tumors capable of displaying prominent signet-ring cell features.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Carcinoma, Signet Ring Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Middle Aged

  • Genetic Alliance. consumer health - Nerve sheath neoplasm.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538053.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Asadi-Amoli F, Khoshnevis F, Haeri H, Jahanzad I, Pazira R, Shahsiah R: Comparative examination of androgen receptor reactivity for differential diagnosis of sebaceous carcinoma from squamous cell and basal cell carcinoma. Am J Clin Pathol; 2010 Jul;134(1):22-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative examination of androgen receptor reactivity for differential diagnosis of sebaceous carcinoma from squamous cell and basal cell carcinoma.
  • Early diagnosis and proper treatment significantly improve the outcome.
  • SEB should be differentiated histopathologically from basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • Along with other markers and morphologic features, AR can be helpful in the diagnosis of SEB and its differentiation from SCC and BCC.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Eyelid Neoplasms / diagnosis. Receptors, Androgen / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Male

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551262.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen
  •  go-up   go-down


33. Trivunić S, Budakov P, Vucković N, Zivojinov M: [Morphological parameters of prostatic adenocarcinoma]. Med Pregl; 2007 Nov-Dec;60(11-12):549-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphological parameters of prostatic adenocarcinoma].
  • The following histologic changes are associated with prostatic carcinomas. prostatic acini are close to one another and present with linear infiltrates in the fibromuscular tissue; cells lining the acini often consist of a single layer, and the basal cell layer is absent; prominent large eosinophilic nucleoli are usually present in malignant cells; nuclear hyperchromatism is rare and it depends on the quality of the tissue fixation; perineural invasion is often observed.
  • Immunohistochemistry is widely used in pathology and clinical diagnosis of prostatic carcinoma, metastases of prostatic origin in staging malignant tumors and in the prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18666594.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


34. Tonini G, Rosini R, Teppa A, Aulenti V, Kalantary F, Tosana M, Bianchi D, Zorzi F: [Adenoid cystic/basal cell carcinoma of the prostate:case report]. Urologia; 2008 Oct-Dec;75(4):245-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic/basal cell carcinoma of the prostate:case report].
  • The adenoid cystic/basal cell carcinoma of the prostate is a rare tumor with distinctive histopathologic features.
  • There are quite few publications in the literature concerning the diagnosis, treatment, and prognosis of this neoplasm.
  • METHODS. A 71-year-old man had an increased PSA value (5.11 ng/dL); the prostatic biopsy examination was positive for adenoid cystic/basal cell carcinoma.
  • The histology examination showed an acinar conventional carcinoma and adenoid cystic/basal cell carcinoma.
  • CONCLUSIONS. Various histologic and immunohistochemical features are helpful in recognizing the adenoid cystic/basal cell carcinoma of the prostate.
  • Clinically, the only difference from a conventional adenocarcinoma is that the PSA value is usually normal or only slightly increased.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086341.001).
  • [ISSN] 0391-5603
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Farah-Klibi F, Ferchiou M, Kourda J, El Amine O, Ferjaoui M, Ben Jilani S, Zermani R: [Parotid basal cell adenoma of membranous type]. Tunis Med; 2009 Feb;87(2):149-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Parotid basal cell adenoma of membranous type].
  • [Transliterated title] Adenome a cellules basales de type membraneux de la parotide.
  • INTRODUCTION: Basal cell adenoma (BCA) is a rare benign neoplasm characterized by the basaloid appearance of the tumour cells and the lack of myxo-chondroid stromal component present in pleomorphic adenoma.
  • AIM: We report a case of basal cell adenoma of membranous type, highly suspected of malignancy because of the presence of mediastinal lymph nodes and pulmonary nodules which finally were related to an associated sarcoidosis.
  • So the diagnosis of metastatic malignant salivary gland tumor was suspected.
  • Finally, the histological examination concluded to a basal cell adenoma of membranous type with sarcoidosis granulomas in the parotid and in the lymph nodes.
  • When the malignancy is suspected, like in our case, this tumor must be differentiated from the basal cell adenocarcinoma using histological criteria.
  • [MeSH-major] Adenoma / diagnosis. Parotid Neoplasms / diagnosis. Sarcoidosis / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. Mediastinum / radiography. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522450.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


36. Vasudev P, Boutross-Tadross O, Radhi J: Basaloid squamous cell carcinoma: two case reports. Cases J; 2009;2:9351
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma: two case reports.
  • Basaloid squamous cell carcinoma (BSCC) is a rare and aggressive variant of squamous cell carcinoma (SCC) that occurs preferentially in the upper aerodigestive tract.
  • BSCC of the head and neck should be distinguished from adenoid cystic carcinoma, small cell neuroendocrine carcinoma, basal cell adenocarcinoma, adenosquamous carcinoma, squamous cell carcinoma, spindle cell squamous carcinoma, mucoepidermoid carcinoma, and adenoid cystic carcinoma.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2008 Jan;44(2):244-50 [18096379.001]
  • [Cites] Auris Nasus Larynx. 2007 Mar;34(1):119-23 [17141998.001]
  • [Cites] Histopathology. 2000 Sep;37(3):218-23 [10971697.001]
  • [Cites] Hum Pathol. 1986 Nov;17(11):1158-66 [3770734.001]
  • [Cites] Ophthalmology. 1993 Nov;100(11):1720-2 [8233401.001]
  • (PMID = 20062602.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2804002
  •  go-up   go-down


37. Long KB, Hornick JL: SOX2 is highly expressed in squamous cell carcinomas of the gastrointestinal tract. Hum Pathol; 2009 Dec;40(12):1768-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SOX2 is highly expressed in squamous cell carcinomas of the gastrointestinal tract.
  • SOX2 is a high-mobility group box embryonic stem cell transcription factor that is expressed in the developing foregut and normal gastric epithelium and is downregulated in intestinal metaplasia of the stomach and esophagus.
  • In addition, SOX2 colocalizes with p63 in the basal layer and plays a critical role in the maintenance of the stratified squamous epithelium of the esophagus.
  • SOX2 expression in squamous cell carcinomas of the gastrointestinal tract has not been previously evaluated.
  • The purpose of this study was to determine whether SOX2 is differentially expressed in squamous cell carcinomas versus adenocarcinomas of the esophagus and rectum/anal canal and to compare its expression to p63, cytokeratin 5/6, and CDX2.
  • In total, 93 tumors were evaluated: 26 esophageal squamous cell carcinomas, 23 esophageal adenocarcinomas, 21 squamous cell carcinomas of the anal canal, and 23 rectal adenocarcinomas.
  • SOX2 was expressed in 81% of esophageal squamous cell carcinomas and 91% of anal canal squamous cell carcinomas, compared to 13% and 17% of esophageal and rectal adenocarcinomas, respectively. p63 was expressed in 96% of esophageal squamous cell carcinomas and 100% of anal canal squamous cell carcinomas; the single squamous cell carcinoma negative for p63 was strongly positive for SOX2.
  • Cytokeratin 5/6 was expressed in most esophageal and anal canal squamous cell carcinomas, but was also positive in 43% of esophageal adenocarcinomas and 13% of rectal adenocarcinomas.
  • In summary, SOX2 is preferentially expressed in squamous cell carcinomas of the esophagus and anal canal compared to adenocarcinomas from these sites.
  • SOX2 may be useful in an immunohistochemical panel to differentiate between squamous cell carcinomas and adenocarcinomas of the gastrointestinal tract.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / metabolism. Gastrointestinal Neoplasms / metabolism. SOXB1 Transcription Factors / biosynthesis
  • [MeSH-minor] Adenocarcinoma / metabolism. Diagnosis, Differential. Homeodomain Proteins / biosynthesis. Humans. Immunohistochemistry. Keratin-5 / biosynthesis. Keratin-6 / biosynthesis. Membrane Proteins / biosynthesis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716157.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / CKAP4 protein, human; 0 / Homeodomain Proteins; 0 / Keratin-5; 0 / Keratin-6; 0 / Membrane Proteins; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors
  •  go-up   go-down


38. Anand BS, Verstovsek G, Cole G: Tubulovillous adenoma of anal canal: a case report. World J Gastroenterol; 2006 Mar 21;12(11):1780-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors arising from the anal canal are usually of epithelial origin and are mostly squamous cell carcinoma or basal cell carcinoma.
  • We present a case of benign anal adenomas arising from the anus, an extremely rare diagnosis.
  • Although seen rarely, it is important to recognize and treat these tumors at an early stage because of their potential to transform into adenocarcinoma.
  • [MeSH-major] Adenoma, Villous / diagnosis. Anus Neoplasms / diagnosis
  • [MeSH-minor] Aged. Anal Canal / pathology. Cell Transformation, Neoplastic. Humans. Male

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):217-9 [15677547.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1634 [8548224.001]
  • (PMID = 16586552.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4124358
  •  go-up   go-down


39. Van Laere SJ, Van den Eynden GG, Van der Auwera I, Vandenberghe M, van Dam P, Van Marck EA, van Golen KL, Vermeulen PB, Dirix LY: Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat; 2006 Feb;95(3):243-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.
  • Most patients have lymph node involvement at the time of diagnosis and 1/3 of the patients have distant metastases.
  • We identified the same cell-of-origin subtypes in IBC as those already described in non-IBC.
  • The robustness of this classification was assessed by an unsupervised hierarchical clustering with an alternative gene set of 141 genes related to the cell-of-origin subtypes, selected using a discriminating score and iterative random permutation testing.
  • The contribution of the different cell-of-origin subtypes to the IBC phenotype was investigated by principal component analysis.
  • Generally, the combined ErbB2-overexpressing and basal-like cluster was more expressed in IBC compared to non-IBC, whereas the combined luminal A, luminal B and normal-like cluster was more pronounced in non-IBC compared to IBC.
  • The presence of the same molecular cell-of-origin subtypes in IBC as in non-IBC does not exclude the specific molecular nature of IBC, since gene lists that characterize IBC and non-IBC are entirely different from gene lists that define the different cell-of-origin subtypes, as evidenced by principal component analysis.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / genetics. Breast Neoplasms / classification. Breast Neoplasms / genetics. Gene Expression Profiling


40. Morikawa T, Nagata M, Tomita K, Kitamura T, Goto A, Chong JM, Fukayama M: Phyllodes tumor of the prostate with exuberant glandular hyperplasia. Pathol Int; 2006 Mar;56(3):158-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reported herein is an unusual case of prostatic phyllodes tumor with exuberant glandular hyperplasia that led to misdiagnosis of adenocarcinoma.
  • Adenocarcinoma of the prostate was diagnosed from a needle biopsy specimen.
  • Histologically, the tumor had an atypical stromal cell proliferation and elongated slit-like glands characteristic of a phyllodes tumor.
  • The tumor was also accompanied by a florid proliferation of small acini, most of which lacked basal cells, a common manifestation of adenocarcinoma in the overall tumor area.
  • The following features of the resected tumor were helpful for concluding that these acini were benign: lack of cytological anaplasia in spite of structural atypia, presence of scattered basal cells confirmed by immunohistochemistry (high-molecular-weight cytokeratin), and histological transition from these acini to apparently benign slit-like glands.
  • The final diagnosis was then made as 'phyllodes tumor of the prostate with exuberant glandular hyperplasia'.
  • Atypical stromal cells might provide a clue for the recognition of this rare tumor at initial diagnosis by needle biopsy.
  • [MeSH-minor] Adenocarcinoma / pathology. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497250.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


41. Uke M, Rekhi B, Ajit D, Jambhekar NA: The use of p63 as an effective immunomarker in the diagnosis of pulmonary squamous cell carcinomas on de-stained bronchial lavage cytological smears. Cytopathology; 2010 Feb;21(1):56-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of p63 as an effective immunomarker in the diagnosis of pulmonary squamous cell carcinomas on de-stained bronchial lavage cytological smears.
  • OBJECTIVES: A diagnosis in pulmonary onco-cytopathology primarily necessitates distinguishing small cell carcinoma (SCLC) from non-small cell carcinoma (NSCLC), which includes squamous cell carcinoma and adenocarcinoma.
  • Lately, p63 antibody has been used for distinguishing squamous cell carcinoma from SCLC and adenocarcinoma.
  • METHODS: A single Papanicolaou-stained conventional smear was de-stained and re-fixed with cold acetone and methanol for immunocytochemical staining with p63 antibody.
  • RESULTS: Out of 100 cases, 21 were cytologically diagnosed as squamous cell carcinoma.
  • Twenty of these showed 2+ or 3+ p63 positivity, whereas one, which was adenocarcinoma on histology, showed 1+ staining.
  • Of seven cases cytologically diagnosed as adenocarcinoma, six showed no p63 staining, whereas one, which was squamous cell carcinoma on histology, showed 1+ staining.
  • The former three were found to be SCLC on histology while the latter was squamous cell carcinoma.
  • The former eight were adenocarcinoma on histology and the latter two were squamous cell carcinoma.
  • The 10 cases that showed 1+ p63 staining were adenocarcinomas (n = 5), squamous cell carcinoma (n = 4) and NSCLC, not otherwise specified (n = 1).
  • Positive staining was seen in normal basal cells, which acted as an internal control.
  • Overall sensitivity of p63 for squamous cell carcinoma was 100% and specificity was 90.4%.
  • CONCLUSIONS: p63 immunostaining on processed cytology smears can be used to help identify squamous cell carcinoma.
  • Its diffuse expression was specific for squamous cell carcinoma while focal staining was also seen in adenocarcinoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Bronchoalveolar Lavage / methods. Bronchoalveolar Lavage Fluid / cytology. Carcinoma, Non-Small-Cell Lung / diagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Transcription Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744186.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


42. Hu J, Zhang Z, Zheng J, Ye W, Tian Z, Zhu H: Unilateral parotid gland involvement with synchronous multiple basal cell adenocarcinomas: case report and review of the literature. J Oral Maxillofac Surg; 2010 Oct;68(10):2579-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral parotid gland involvement with synchronous multiple basal cell adenocarcinomas: case report and review of the literature.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20096979.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


43. Seethala RR, Pasha TL, Raghunath PN, Livolsi VA, Zhang PJ: The selective expression of CD43 in adenoid cystic carcinoma. Appl Immunohistochem Mol Morphol; 2008 Mar;16(2):165-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD43 immunoreactivity with 2 different antibodies was detected mainly in ACC but also 1 membranous type basal cell adenocarcinoma and 1 colonic adenocarcinoma.

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18227725.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD43; 0 / RNA, Messenger; 0 / UN1 sialoglycoprotein, human
  •  go-up   go-down


44. Ghigna MR, Drak Alsibai K, Porras J, Palazzo L, Godchaux JM, Fabre M: Deep-seated rectal/anal basaloid carcinoma: useful immunocytochemistry in rare squamous cell carcinoma variants. Cytopathology; 2009 Oct;20(5):315-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deep-seated rectal/anal basaloid carcinoma: useful immunocytochemistry in rare squamous cell carcinoma variants.
  • OBJECTIVES: To report the cytological aspects of ano-rectal basaloid carcinoma (BC) variant in endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) conventional and liquid-based cytology (LBC), in a series of 10 cases of deep-seated squamous cell carcinomas (SCC), and to discuss the diagnostic difficulties in interpreting the morphology and immunocytochemical findings.
  • Of these two cases, only one was correctly diagnosed by EUS-FNA specimen, whereas in the second case, the initial cytological diagnosis was poorly differentiated adenocarcinoma and the final diagnosis of basaloid carcinoma variant was established on surgical resection.
  • Immunocytochemistry (ICC) using CK7, CK20 and CK34betae12 on FNA specimens confirmed the diagnosis retrospectively.
  • CONCLUSION: The diagnosis of basaloid variant of SCC in a rectal location can be very difficult, both on account of the uncommon location and because of the low specificity of morphological aspects on EUS-FNA smears.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell. Immunohistochemistry / methods. Neoplasms, Basal Cell. Rectal Neoplasms

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540877.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


45. Lanoy E, Costagliola D, Engels EA: Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults. Int J Cancer; 2010 Apr 1;126(7):1724-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study comprised 29,926 skin cancer cases (excluding basal cell and squamous cell carcinomas) and 119,704 controls, frequency-matched by gender, age and calendar year (1987-2002).
  • Medicare claims identified solid-organ transplantation or HIV infection before cancer diagnosis/control selection.
  • Solid-organ transplantation was also associated with increased risks of Merkel cell carcinoma (N = 1,286; OR [95%CI] 4.95 [2.62-9.34]) and other cutaneous sarcomas (N = 972; 4.19 [1.83-9.56]).
  • [MeSH-major] Adenocarcinoma / etiology. HIV Infections / complications. HIV Infections / therapy. HIV-1 / pathogenicity. Organ Transplantation / adverse effects. Skin Neoplasms / etiology


46. Ihemelandu CU, Naab TJ, Mezghebe HM, Makambi KH, Siram SM, Leffall LD Jr, Dewitty RL Jr, Frederick WA: Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African American women. Am J Surg; 2008 Feb;195(2):153-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African American women.
  • BACKGROUND: The aim of this study was to evaluate the prognostic significance of the basal cell-like molecular breast cancer subtype with respect to locoregional recurrence and distant metastasis in African American women treated for breast cancer.
  • Compared with the other molecular subtypes the basal cell-like subtype showed a statistically significant association to distant metastasis: 15 (42.9%) vs 13 (37.1%), 4 (11.4%), and 3 (8.6%) (P < .001), respectively, for luminal A, Her-2/neu, and luminal B subtypes.
  • The basal cell-like subtype was an independent predictor of distant metastasis (odds ratio, 5.8; 95% confidence interval, 1.5-22.0, P = .009).
  • The molecular subtypes showed no statistically significant difference with respect to locoregional treatment administered and tumor stage at time of diagnosis.
  • CONCLUSIONS: The basal cell-like molecular breast cancer subtype is an independent predictor of distant metastasis in African American women.
  • [MeSH-major] Adenocarcinoma / ethnology. Adenocarcinoma / secondary. African Americans / genetics. Breast Neoplasms / ethnology. Breast Neoplasms / genetics. Neoplasm Recurrence, Local / genetics


47. Chung SW, Kwon SY, Jung KY, Woo JS: Synchronous double primary cancers of the unilateral parotid gland. Acta Otolaryngol; 2007 Feb;127(2):209-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report a 39-year-old woman who exhibited basal cell adenocarcinoma and mucoepidermoid carcinoma simultaneously in the left parotid gland.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Mucoepidermoid / pathology. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364354.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


48. Petersen SK, Bjørndal K, Krogdahl A, Godballe C: [Basal cell adenocarcinoma of the sublingual gland]. Ugeskr Laeger; 2010 Feb 15;172(7):551-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal cell adenocarcinoma of the sublingual gland].
  • [MeSH-major] Adenocarcinoma / pathology. Sublingual Gland Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Edema / diagnosis. Female. Humans. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20156409.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


49. Parashar P, Baron E, Papadimitriou JC, Ord RA, Nikitakis NG: Basal cell adenocarcinoma of the oral minor salivary glands: review of the literature and presentation of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jan;103(1):77-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of the oral minor salivary glands: review of the literature and presentation of two cases.
  • Basal cell adenocarcinoma (BCA) is an unusual salivary gland malignancy that very rarely affects the minor glands.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178498.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


50. Andreadis D, Nomikos A, Epivatianos A, Poulopoulos A, Barbatis C: Basaloid squamous cell carcinoma versus basal cell adenocarcinoma of the oral cavity. Pathology; 2005 Dec;37(6):560-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma versus basal cell adenocarcinoma of the oral cavity.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Carcinoma, Squamous Cell / pathology. Oropharyngeal Neoplasms / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry


51. Lisovsky M, Ogawa F, Dresser K, Woda B, Lauwers GY: Loss of cell polarity protein Lgl2 in foveolar-type gastric dysplasia: correlation with expression of the apical marker aPKC-zeta. Virchows Arch; 2010 Dec;457(6):635-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of cell polarity protein Lgl2 in foveolar-type gastric dysplasia: correlation with expression of the apical marker aPKC-zeta.
  • Since atypical protein kinase C (aPKC) is a partner of Lgl2 in the control of apical-basal polarity we also investigated whether aPKC-zeta can compliment Lgl2 as a marker of dysplasia.
  • Routinely processed specimens included 64 normal mucosa, 35 reactive gastropathies, 31 chronic gastritides, 65 gastric dysplasias (25 foveolar; 40 adenomatous), and 34 gastric adenocarcinomas.
  • Apical aPKC-zeta staining was lost in 97% of gastric adenocarcinomas.
  • Our data suggest a role of Lgl2 immunohistochemistry as an adjunct in the diagnosis of foveolar-type gastric dysplasia. aPKC-zeta had moderate sensitivity as a marker of gastric dysplasia and additional studies are needed to establish its role in the diagnosis of dysplasia.
  • [MeSH-major] Cell Polarity / physiology. Cytoskeletal Proteins / metabolism. Precancerous Conditions / metabolism. Protein Kinase C / metabolism. Stomach Diseases / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers / metabolism. Diagnosis, Differential. Gastritis / diagnosis. Gastritis / metabolism. Gastritis / pathology. Humans. Intestinal Mucosa / metabolism. Sensitivity and Specificity. Stomach Neoplasms / diagnosis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1997 Feb;28(2):127-33 [9023391.001]
  • [Cites] J Cell Biol. 2005 Jul 18;170(2):273-83 [16027223.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1376-80 [16251968.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):786-95 [12920223.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):166-70 [11668493.001]
  • [Cites] Dev Cell. 2004 Jun;6(6):845-54 [15177032.001]
  • [Cites] Histopathology. 1993 Oct;23(4):341-8 [8300069.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12519-24 [16116079.001]
  • [Cites] Am J Surg Pathol. 2009 Feb;33(2):186-93 [18830123.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3231-3 [1317264.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):167-76 [10680883.001]
  • [Cites] Science. 1978 Jun 30;200(4349):1448-59 [96525.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):813-29, vi [17996792.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Mod Pathol. 2009 Jul;22(7):977-84 [19407852.001]
  • [Cites] Oncogene. 2005 Apr 28;24(19):3100-9 [15735678.001]
  • [Cites] Gut. 1999 Nov;45(5):784-90 [10517922.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):994-1005 [7927322.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1778(3):614-30 [18005931.001]
  • [Cites] Nat Cell Biol. 2003 Apr;5(4):301-8 [12629547.001]
  • [Cites] Mod Pathol. 2010 Jan;23(1):1-11 [19838164.001]
  • [Cites] Nat Cell Biol. 2003 Feb;5(2):166-70 [12545176.001]
  • [Cites] Cell. 2008 Nov 28;135(5):865-78 [19041750.001]
  • [Cites] Mod Pathol. 2010 Jan;23 (1):54-61 [19820687.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1276-85 [12360042.001]
  • [Cites] J Clin Pathol. 1990 Apr;43(4):303-6 [2341566.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1909-25 [15314019.001]
  • [Cites] Curr Biol. 2003 Apr 29;13(9):734-43 [12725730.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3503-6 [12067995.001]
  • [Cites] Oncogene. 2004 Nov 11;23(53):8688-94 [15467749.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8905-11 [16204062.001]
  • [Cites] Am J Surg Pathol. 2009 Jun;33(6):886-93 [19194279.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):524-33 [18300795.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6469-79 [17085661.001]
  • [Cites] Mod Pathol. 2010 Jun;23 (6):834-43 [20228780.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4699-713 [17297461.001]
  • [Cites] Development. 2005 Mar;132(5):977-86 [15689379.001]
  • [Cites] Dig Liver Dis. 2008 Aug;40(8):641-9 [18424243.001]
  • [Cites] Science. 2000 Jul 7;289(5476):113-6 [10884224.001]
  • [Cites] Curr Biol. 2004 Aug 24;14(16):R674-85 [15324689.001]
  • (PMID = 20941506.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytoskeletal Proteins; 0 / Hugl-2 protein, human; EC 2.7.11.1 / protein kinase C zeta; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


52. Cavalcanti Fde B, Alves VA, Pereira J, Kanamura CT, Wakamatsu A, Saldanha LB: Proliferative lesions of prostate: a multivariate approach to differential diagnosis. Pathol Oncol Res; 2005;11(2):103-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferative lesions of prostate: a multivariate approach to differential diagnosis.
  • Prostatic needle biopsies from 142 patients were studied: 61 cases were "benign", 19 atypical small acinar proliferation, 31 high-grade prostatic intraepithelial neoplasia, and 31 adenocarcinoma.
  • Of these parameters, seven (glandular fusion, crystalloids, nucleolomegaly, papillary architecture, visibility of basal cell layer, areas of normal luminal cell nucleus/cytoplasm ratio and areas of high luminal cell nucleus/cytoplasm ratio) remained significant in discriminating the groups.
  • Multivariate analysis selected a small panel of histological features as those most helpful in the differential diagnosis of proliferative lesions in prostate biopsies.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Acinar Cell / diagnosis. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Needle. Cell Proliferation. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):840-8 [9669346.001]
  • [Cites] Am J Surg Pathol. 1995 Mar;19(3):251-60 [7532918.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):925-31 [10435562.001]
  • [Cites] Cancer Res. 1985 Aug;45(8):3663-7 [2410099.001]
  • [Cites] J Urol. 1974 Jan;111(1):58-64 [4813554.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):273-9 [1555838.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(3):191-6 [1696762.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):230-2 [12610105.001]
  • [Cites] Arch Pathol Lab Med. 1994 Mar;118(3):260-4 [7510946.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1489-95 [9414193.001]
  • [Cites] Am J Clin Pathol. 1983 Dec;80(6):850-4 [6195916.001]
  • [Cites] Urology. 1998 May;51(5):749-57; discussion 757-8 [9610588.001]
  • [Cites] Am J Surg Pathol. 1999 Feb;23(2):147-52 [9989840.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] Am J Surg Pathol. 1995 Sep;19(9):1068-76 [7544958.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):821-31 [8037296.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):819-32 [8375853.001]
  • [Cites] J Clin Pathol. 1997 Sep;50(9):775-82 [9389981.001]
  • [Cites] Virchows Arch. 1998 Nov;433(5):397-405 [9849853.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):298-310 [8454275.001]
  • [Cites] AMA Arch Pathol. 1953 Feb;55(2):131-41 [13007281.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1073-7 [9737239.001]
  • [Cites] Hum Pathol. 1988 Dec;19(12):1425-33 [2461340.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):242-8 [1372878.001]
  • [Cites] Arch Pathol Lab Med. 2002 May;126(5):554-61 [11958660.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1151-60 [12218571.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):64-71 [3943853.001]
  • [Cites] Urology. 1995 Jun;45(6):981-6 [7539563.001]
  • [Cites] In Vivo. 2002 Nov-Dec;16(6):557-66 [12494901.001]
  • [Cites] Am J Clin Pathol. 1997 Feb;107(2):219-23 [9024071.001]
  • [Cites] Am J Surg Pathol. 1999 Oct;23 (10 ):1173-83 [10524518.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):932-6 [10435563.001]
  • [Cites] Rev Invest Clin. 1997 Jan-Feb;49(1):37-40 [9114721.001]
  • [Cites] Histopathology. 1996 Jul;29(1):11-9 [8818689.001]
  • [Cites] Am J Pathol. 1987 Feb;126(2):384-95 [2435158.001]
  • (PMID = 15999155.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


53. Breuninger S, Reidenbach S, Sauer CG, Ströbel P, Pfitzenmaier J, Trojan L, Hofmann I: Desmosomal plakophilins in the prostate and prostatic adenocarcinomas: implications for diagnosis and tumor progression. Am J Pathol; 2010 May;176(5):2509-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmosomal plakophilins in the prostate and prostatic adenocarcinomas: implications for diagnosis and tumor progression.
  • The plakophilins, members of the armadillo-repeat family, consist of three different proteins (PKP1-3) that are specifically recruited to desmosomal plaques in a highly cell type-specific manner.
  • Using immunofluorescence, immunoelectron microscopy, and immunoblot, we found that all three plakophilins occurred in luminal and basal cells of the pseudostratified prostate epithelium.
  • The analysis of 135 cases of prostatic adenocarcinomas grouped into tumors with low (Gleason score < or = 6), intermediate (Gleason score 7), and high Gleason score (8 < or = Gleason score < or = 10) showed that the expression of PKP1 was reduced or lost in adenocarcinomas with high Gleason scores.
  • The expression of PKP2 was unchanged in all prostatic adenocarcinomas analyzed.
  • In DU 145 cell lines with either overexpression or knockdown of PKP3, both imbalances resulted in fewer desmosomal cell contacts.
  • [MeSH-major] Adenocarcinoma / metabolism. Desmosomes / metabolism. Gene Expression Regulation, Neoplastic. Plakophilins / metabolism. Prostate / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Aged. Cell Adhesion. Cell Proliferation. Disease Progression. Humans. Male. Middle Aged. Phenotype

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7795-800 [11416169.001]
  • [Cites] J Cell Biochem. 2005 Oct 1;96(2):390-403 [15988759.001]
  • [Cites] Mol Biol Cell. 2002 May;13(5):1665-76 [12006661.001]
  • [Cites] Exp Cell Res. 2003 Apr 15;285(1):114-30 [12681292.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):565-72 [12827610.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S3-10 [12850522.001]
  • [Cites] Histopathology. 2003 Sep;43(3):209-19 [12940773.001]
  • [Cites] J Cutan Pathol. 2003 Nov;30(10):621-30 [14744087.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Apr;5(4):271-81 [15071552.001]
  • [Cites] J Cell Biol. 2004 Oct 11;167(1):149-60 [15479741.001]
  • [Cites] J Cell Biol. 1988 May;106(5):1679-91 [3131348.001]
  • [Cites] Differentiation. 1994 Dec;58(2):113-31 [7890138.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]
  • [Cites] J Cell Biol. 1996 Nov;135(4):1009-25 [8922383.001]
  • [Cites] J Invest Dermatol. 1997 Feb;108(2):139-46 [9008225.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Cell Tissue Res. 1997 Dec;290(3):481-99 [9369526.001]
  • [Cites] Br J Dermatol. 1999 Feb;140(2):297-307 [10233227.001]
  • [Cites] Differentiation. 1999 Jun;64(5):277-90 [10374264.001]
  • [Cites] Differentiation. 1999 Jun;64(5):291-306 [10374265.001]
  • [Cites] J Cell Sci. 1999 Jul;112 ( Pt 14):2265-76 [10381383.001]
  • [Cites] Exp Cell Res. 1999 Aug 1;250(2):452-64 [10413599.001]
  • [Cites] Eur J Cell Biol. 2005 Mar;84(2-3):189-204 [15819400.001]
  • [Cites] Eur J Cell Biol. 2005 Mar;84(2-3):205-14 [15819401.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Mol Biol Cell. 2006 Mar;17(3):1388-98 [16407409.001]
  • [Cites] Hum Pathol. 2006 May;37(5):613-22 [16647960.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1773(1):78-88 [17030444.001]
  • [Cites] Histopathology. 2007 Jul;51(1):87-97 [17593084.001]
  • [Cites] Cell Commun Adhes. 2007 Mar-Jun;14(2-3):99-109 [17668353.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1778(3):660-9 [17854762.001]
  • [Cites] J Invest Dermatol. 2008 Jun;128(6):1375-85 [18079750.001]
  • [Cites] J Cell Biol. 2008 May 19;181(4):605-13 [18474624.001]
  • [Cites] Int J Cancer. 2008 Nov 15;123(10):2303-14 [18729189.001]
  • [Cites] Histochem Cell Biol. 2008 Nov;130(5):943-56 [18600340.001]
  • [Cites] J Cell Sci. 2009 Jan 1;122(Pt 1):21-4 [19092057.001]
  • [Cites] Cell Tissue Res. 2008 Dec;334(3):381-99 [19005682.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7102-10 [16103059.001]
  • [Cites] Eur J Cell Biol. 2001 Sep;80(9):567-79 [11675932.001]
  • (PMID = 20348237.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PKP1 protein, human; 0 / PKP3 protein, human; 0 / Plakophilins
  • [Other-IDs] NLM/ PMC2861115
  •  go-up   go-down


54. Schowinsky JT, Epstein JI: Distorted rectal tissue on prostate needle biopsy: a mimicker of prostate cancer. Am J Surg Pathol; 2006 Jul;30(7):866-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On rare occasion distorted rectal glands can mimic prostatic adenocarcinoma, an issue not previously addressed in the peer-reviewed literature.
  • Immunohistochemical results further mimicked prostate cancer with negative stains for the basal cell markers high-molecular weight cytokeratin (n=6) and p63 (n=4), and positive stains for racemase in 4 of 5 biopsies.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle. Diagnostic Errors. Prostatic Neoplasms / pathology. Rectum / anatomy & histology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Intestinal Mucosa / anatomy & histology. Intestinal Mucosa / metabolism. Keratins / metabolism. Male. Mucins / metabolism. Prostate-Specific Antigen / metabolism. Racemases and Epimerases / metabolism


55. Maddox PT, Paydarfar JA, Black CC, Eskey CJ: Pathology quiz case 1. Basal cell adenocarcinoma (BCAC) of a minor salivary gland. Arch Otolaryngol Head Neck Surg; 2010 Mar;136(3):310, 312-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology quiz case 1. Basal cell adenocarcinoma (BCAC) of a minor salivary gland.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231656.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Puebla-Mora AG, Heras A, Cano-Valdez AM, Domínguez-Malagón H: Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study. Ann Diagn Pathol; 2006 Aug;10(4):205-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human telomerase detected by in situ hybridization has been demonstrated to be a useful tool for the diagnosis of malignancy and has also been tested by reverse transcriptase-polymerase chain reaction in several tumors such as hepatic cell carcinoma, melanoma, colonic carcinoma, gastric carcinoma, biliary carcinoma, breast carcinoma, mesothelioma, lung carcinoma, female tract carcinoma, and prostatic carcinoma.
  • Fifty-five specimens of diverse prostatic lesions were selected for study (43 needle biopsies and 12 transurethral resections); there were 61 malignancies (47 infiltrating carcinomas and 14 high-grade prostatic intraepithelial neoplasias [PIN]) and 29 benign lesions (10 basal cell hyperplasias, 12 nodular hyperplasias, 4 chronic prostatitis, and 3 atrophic glands).
  • Signal for hTERT nucleolar was detected in 31 of 47 infiltrating adenocarcinomas, in 11 of 14 PIN, and in none of 27 benign lesions (sensitivity, 71%; specificity, 100%).
  • Diffuse cytoplasmic positivity for AMACR was found in 37 of 41 infiltrating adenocarcinomas, in 7 of 7 PIN, and in 6 of 22 benign lesions (sensitivity, 91%; specificity, 72%).
  • [MeSH-major] Adenocarcinoma / enzymology. DNA-Binding Proteins / metabolism. Immunoenzyme Techniques / methods. Prostatic Intraepithelial Neoplasia / enzymology. Prostatic Neoplasms / enzymology. Racemases and Epimerases / metabolism. Telomerase / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844561.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; EC 2.7.7.49 / Telomerase; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


57. Serap D, Ozlem S, Melike Y, Alper D, Aynur A, Ata Türker A, Ardıç S: Acanthosis nigricans in a patient with lung cancer: a case report. Case Rep Med; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thoracic computed tomography demonstrated a hypodense mass lesion with a dimension of 5 x 5.5 cm at the center of basal segment bronchi of the left pulmonary lobe.
  • The result of the histopathologic examination of the endobronchial tissue biopsy was reported as non-small cell (adenocarcinoma) lung cancer.
  • In conclusion, there are skin lesions that accompany lung cancer and we believe that these should be considered for differential diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2002 Feb;84(2):332-4 [11812096.001]
  • [Cites] Diabetes Care. 2002 Jun;25(6):1009-14 [12032107.001]
  • [Cites] Dermatol Clin. 2002 Jul;20(3):523-32 [12170885.001]
  • [Cites] J Dermatol Surg Oncol. 1980 Nov;6(11):923-7 [6257767.001]
  • [Cites] Thorax. 1988 May;43(5):414-5 [2848329.001]
  • [Cites] Dermatologica. 1988;176(3):133-7 [3378650.001]
  • [Cites] J Am Acad Dermatol. 1991 Aug;25(2 Pt 2):361-5 [1894773.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1992 Nov;30(11):1991-5 [1484439.001]
  • [Cites] J Am Acad Dermatol. 1994 Jul;31(1):1-19; quiz 20-2 [8021347.001]
  • [Cites] Cancer. 1962 Mar-Apr;15:364-82 [13882755.001]
  • [Cites] Curr Opin Oncol. 1999 Mar;11(2):139-44 [10188080.001]
  • [Cites] Int J Dermatol. 2005 Jan;44(1):45-7 [15663660.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2009 Dec;15(6):397-400 [20081750.001]
  • [Cites] Pol Arch Med Wewn. 2009 Mar;119(3):180-3 [19514649.001]
  • [Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 2):357-62 [10640933.001]
  • [Cites] Diabetes Care. 2004 Jun;27(6):1412-6 [15161797.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):541-3 [12963928.001]
  • (PMID = 20811563.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Ramos Soler D, Mayordomo Aranda E, Calatayud Blas A, Rubio Briones J, Solsona Narbón E, Llombart Bosch A: [Usefulness of bcl-2 expression as a new basal cell marker in prostatic pathology]. Actas Urol Esp; 2006 Apr;30(4):345-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Usefulness of bcl-2 expression as a new basal cell marker in prostatic pathology].
  • [Transliterated title] Utilidad de bcl-2 como nuevo marcador de expresión de células basales en patología prostática.
  • INTRODUCTION AND OBJECTIVES: The diagnosis of invasive adenocarcinoma of the prostate is often difficult in needle prostatic cores, where, additionally, the assessment of the presence of basal cells has demonstrated to be of paramount importance.
  • In our study, we analyzed comparatively the expression of 34betaE12, p63, bcl-2 and alpha-methylacyl-CoA racemase in order to evaluate the usefulness of bcl-2 as a new marker of the basal cells in prostatic pathology.
  • METHODS AND RESULTS: This study comprises radical prostatectomy specimens from 48 patients which were studied in order to determine the lack of staining of basal cells in invasive tumor areas together with the expression of racemase.
  • Likewise, the presence of basal cells in areas of atrophy, hyperplasia, adenosis, and high-grade prostatic intraepithelial neoplasia (PIN) was also examined.
  • Within the areas of adenosis and PIN a discontinuous pattern of basal cell expression was found in some cases.
  • In 2 out of 48 cases (4,2%) of invasive carcinoma a weak bcl-2 expression without a basal cell distribution was found.
  • CONCLUSIONS: In addition to classical markers, we demonstrated the diagnostic value of bcl-2 as a new basal cell marker.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Epithelial Cells / chemistry. Neoplasm Proteins / analysis. Prostatic Neoplasms / chemistry. Proto-Oncogene Proteins c-bcl-2 / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16838605.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CK-34 beta E12; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


59. Gupta M, de Leval L, Selig M, Oliva E, Nielsen GP: Uterine tumors resembling ovarian sex cord tumors: an ultrastructural analysis of 13 cases. Ultrastruct Pathol; 2010 Feb;34(1):16-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Features included cells with frequent organoid, nested or cord-like arrangement (8), lumen formation (2; one of which showed surface microvilli), nuclei with irregular indentations (8), intermediate filaments (13), prominent paranuclear aggregates (5), cell junctions (9), desmosome-like junctions (2), tonofilaments (2), basal lamina (1), and cytoplasmic lipid droplets (7; prominent in 3).
  • [MeSH-major] Adenocarcinoma / diagnosis. Ovarian Neoplasms / diagnosis. Sex Cord-Gonadal Stromal Tumors / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Calbindin 2. Cell Nucleus / ultrastructure. Cytoplasmic Structures / ultrastructure. Desmosomes / ultrastructure. Diagnosis, Differential. Female. Humans. Intermediate Filaments / ultrastructure. Keratins / analysis. Microscopy, Electron, Transmission. S100 Calcium Binding Protein G / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20070149.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 68238-35-7 / Keratins
  •  go-up   go-down


60. Husain A, Blumenschein G, Esmaeli B: Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol; 2008 Mar;47(3):276-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid.
  • OBJECTIVE: To report the management and outcomes in patients with metastatic eyelid sebaceous cell carcinoma.
  • METHODS: The clinical records of four patients with metastatic eyelid sebaceous cell carcinoma treated between January 1999 and August 2006 were reviewed.
  • Time from diagnosis of eyelid carcinoma to metastasis ranged from 0 to 62 months.
  • One patient developed lung metastasis 5 years after the diagnosis of eyelid tumor; she was treated with systemic chemotherapy followed by subtotal lung resection.
  • The follow-up time from diagnosis of metastasis to last contact or death ranged from 1 month to 3 years (median of 21 months).
  • CONCLUSION: Eyelid sebaceous cell carcinoma can result in systemic metastasis and death.
  • [MeSH-major] Adenocarcinoma, Sebaceous / secondary. Bone Neoplasms / secondary. Eyelid Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Parotid Neoplasms / secondary. Sebaceous Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Chalazion / diagnosis. Diagnostic Errors. Female. Humans. Lymphatic Metastasis / radiotherapy. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289332.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Hosler GA, Epstein JI: Basal cell hyperplasia: an unusual diagnostic dilemma on prostate needle biopsies. Hum Pathol; 2005 May;36(5):480-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell hyperplasia: an unusual diagnostic dilemma on prostate needle biopsies.
  • Basal cell hyperplasia (BCH) is a well-recognized entity on transurethral resection specimens, but it is an uncommon finding on prostatic needle biopsies, and the diagnostic difficulties with it have not been fully defined on this material.
  • In all cases, the focus of BCH was referred for consultation to rule out adenocarcinoma.
  • Other minor patterns included cribriform (5), pseudocribriform (4), cords (1), and adenoid basal (1).
  • Basal cell hyperplasia, as a mimicker of cancer, is an uncommon entity encountered on prostatic needle biopsies.
  • Helpful features for its diagnosis include solid nests, pseudocribriform glands, multilayering of cells, calcifications, and cellular stroma.
  • Immunohistochemistry can be useful for documenting the basal cell layer and demonstrating negative racemase staining.
  • [MeSH-minor] Adenocarcinoma / pathology. Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Prostatic Neoplasms / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948114.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Stewart J, Fleshner N, Cole H, Sweet J: Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study. J Clin Pathol; 2007 Jul;60(7):773-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Current ancillary markers for diagnosis in prostate biopsies include p63 and alpha-methylacyl-CoA racemase (AMACR).
  • Staining was evaluated in benign and atrophic glands, high-grade prostatic intraepithelial neoplasia (HGPIN), and prostatic adenocarcinoma.
  • RESULTS: Diffuse cytoplasmic expression of ANXII correlated with p63 reactivity in basal cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Annexin A2 / metabolism. Biomarkers, Tumor / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. DNA-Binding Proteins / metabolism. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Proteins / metabolism. Organ Size. Prostate / pathology. Prostatectomy. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Intraepithelial Neoplasia / surgery. Racemases and Epimerases / metabolism. Trans-Activators / metabolism. Transcription Factors. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):916-20 [14713853.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):13-9 [16330937.001]
  • [Cites] J Cell Biochem. 2004 Mar 1;91(4):852-63 [14991775.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3450-5 [14985510.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):328-48 [14976539.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3539-45 [15226377.001]
  • [Cites] Mol Cancer. 2003 Oct 8;2:34 [14613585.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):1008-13 [15297968.001]
  • [Cites] Histopathology. 2004 Sep;45(3):218-25 [15330799.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):368-74 [15338305.001]
  • [Cites] J Biol Chem. 1986 Jun 5;261(16):7247-52 [2940239.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jun;83(12):4258-62 [3012561.001]
  • [Cites] Mol Cell Biol. 1990 Jun;10(6):3216-23 [2160596.001]
  • [Cites] Differentiation. 1993 Mar;52(3):229-37 [8387039.001]
  • [Cites] Carcinogenesis. 1993 Dec;14(12):2575-9 [8269629.001]
  • [Cites] Eur J Biochem. 1994 Jun 1;222(2):313-23 [8020470.001]
  • [Cites] J Biol Chem. 1995 Jun 16;270(24):14399-404 [7782301.001]
  • [Cites] Oncol Res. 1994;6(12):561-7 [7787249.001]
  • [Cites] Prostate. 1997 Sep 15;33(1):32-7 [9294624.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 7;1477(1-2):215-30 [10708859.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1769-75 [11106548.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6331-4 [11522620.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1419-26 [11745218.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2220-6 [11956072.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):926-31 [12131161.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1588-96 [12459625.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1475-85 [12629510.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):772-8 [12766580.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1128-33 [12883245.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):579-87 [15832080.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):449-61 [15928709.001]
  • [Cites] Histol Histopathol. 2005 Jul;20(3):673-80 [15944914.001]
  • [Cites] Histopathology. 2005 Jul;47(1):1-16 [15982318.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1219-23 [16287434.001]
  • [Cites] Cell Prolif. 2005 Dec;38(6):363-74 [16300650.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):307-15 [14599294.001]
  • (PMID = 16916997.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A2; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Other-IDs] NLM/ PMC1995785
  •  go-up   go-down


63. Plaza JA, Ortega PF, Stockman DL, Suster S: Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: a clinicopathologic and immunohistochemical study of 79 cases. J Cutan Pathol; 2010 Apr;37(4):403-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: a clinicopathologic and immunohistochemical study of 79 cases.
  • Thirty seven primary tumors and 42 cutaneous metastatic adenocarcinomas were evaluated.
  • The 37 primary cutaneous tumors included 14 cases of benign adnexal tumors, 9 malignant skin adnexal neoplasms, and 14 primary squamous and basal cell carcinomas.
  • The 42 metastatic adenocarcinomas all corresponded to metastases from patients with a well-documented history of a primary tumor at another location.
  • We found variable positivity with podoplanin in all primary cutaneous neoplasms including spiradenoma (6/6), hidradenoma (2/4), cylindroma (3/3), desmoplastic trichilemmoma (1/1), poorly differentiated squamous cell carcinoma (4/4), sebaceous carcinoma (1/1), basal cell carcinoma (4/10), trichilemmal carcinoma (2/2), eccrine carcinoma (3/3), microcystic adnexal carcinoma (1/1), adnexal carcinoma NOS (1/1), and porocarcinoma (1/1).
  • The results of our study suggest that the combined expression of p63 and podoplanin are a useful adjunct for the diagnosis of skin tumors in the clinical setting of a questionable metastasis and may be relatively specific for distinguishing primary skin tumors from metastatic carcinomas to the skin.
  • [MeSH-major] Adenocarcinoma / metabolism. Membrane Glycoproteins / metabolism. Membrane Proteins / metabolism. Skin / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377670.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / PDPN protein, human
  •  go-up   go-down


64. Hameed O, Humphrey PA: Pseudoneoplastic mimics of prostate and bladder carcinomas. Arch Pathol Lab Med; 2010 Mar;134(3):427-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Pseudoneoplastic lesions in the prostate include those of prostatic epithelial origin, the most common being atrophy, adenosis (atypical adenomatous hyperplasia), basal cell hyperplasia, and crowded benign glands, as well as those of nonprostatic origin, such as seminal vesicle epithelium.
  • Such lesions often mimic lower-grade prostatic adenocarcinoma, whereas others, such as clear cell cribriform hyperplasia and granulomatous prostatitis, for example, are in the differential diagnosis of Gleason adenocarcinoma, Gleason grade 4 or 5.
  • [MeSH-major] Granuloma, Plasma Cell / diagnosis. Prostatic Diseases / diagnosis. Urinary Bladder Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Prostatic Neoplasms / classification. Prostatic Neoplasms / diagnosis. Urinary Bladder Neoplasms / classification. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20196670.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 83
  •  go-up   go-down


65. Mayes DC, Patterson JW, Ramnani DM, Mills SE: alpha-methylacyl coenzyme A racemase is immunoreactive in extramammary Paget disease. Am J Clin Pathol; 2007 Apr;127(4):567-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • alpha-Methylacyl-coenzyme A racemase (AMACR) has become a common tool in the diagnosis of morphologically difficult prostatic carcinoma and often is used in combination with the basal cell markers p63 and 34betaE12.
  • [MeSH-major] Adenocarcinoma / complications. Biomarkers, Tumor / analysis. Paget Disease, Extramammary / complications. Paget Disease, Extramammary / metabolism. Prostatic Neoplasms / complications. Racemases and Epimerases / metabolism

  • Genetic Alliance. consumer health - Paget Disease.
  • Genetic Alliance. consumer health - Paget disease, extramammary.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17369131.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


66. McHugh JB, Hoschar AP, Dvorakova M, Parwani AV, Barnes EL, Seethala RR: p63 immunohistochemistry differentiates salivary gland oncocytoma and oncocytic carcinoma from metastatic renal cell carcinoma. Head Neck Pathol; 2007 Dec;1(2):123-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 immunohistochemistry differentiates salivary gland oncocytoma and oncocytic carcinoma from metastatic renal cell carcinoma.
  • Metastatic renal cell carcinoma (RCC) can pose diagnostic challenges in the head and neck often resembling benign and malignant oncocytic lesions.
  • Morphologic features evaluated were cytoplasmic character (clear versus oncocytic), Fuhrman nuclear grade, mitotic rate, growth pattern, presence of lumens/blood lakes and stromal characteristics.
  • Tumors were stained with antibodies to p63, renal cell carcinoma marker (RCCm), CD10, and vimentin.
  • Eight benign oncocytic tumors (29%) had clear cell features while 6 metastatic RCC (37%) had oncocytic features.
  • All primary salivary gland tumors were positive for p63, predominately in basal cell-type distribution.
  • While clinical history and morphology usually are adequate, demonstration of p63 staining can definitively exclude metastatic RCC from the differential diagnosis of similar appearing tumors in salivary glands, namely oncocytoma and oncocytic carcinoma, with 100% specificity and sensitivity.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenoma, Oxyphilic / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Membrane Proteins / metabolism. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Predictive Value of Tests

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1099-105 [10594758.001]
  • [Cites] Otolaryngol Head Neck Surg. 2002 Jun;126(6):657-62 [12087334.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Adv Anat Pathol. 2002 Sep;9(5):280-9 [12195217.001]
  • [Cites] Laryngoscope. 2002 Sep;112(9):1598-602 [12352670.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):428-36 [12447671.001]
  • [Cites] J Histochem Cytochem. 2003 Feb;51(2):133-9 [12533521.001]
  • [Cites] J Histochem Cytochem. 2003 Aug;51(8):1097-9 [12871991.001]
  • [Cites] Lab Invest. 1970 Dec;23(6):567-80 [5530737.001]
  • [Cites] Mich Med. 1971 Jul;70(16):616-8 [5571989.001]
  • [Cites] Laryngoscope. 1973 Jun;83(6):898-905 [4711327.001]
  • [Cites] Laryngoscope. 1981 Apr;91(4):517-9 [6261053.001]
  • [Cites] South Med J. 1981 Sep;74(9):1050-2 [7280750.001]
  • [Cites] Pathol Res Pract. 1986 Dec;181(6):684-92 [3562340.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Jan;65(1):61-6 [3422397.001]
  • [Cites] Hum Pathol. 1988 Jul;19(7):862-7 [3402976.001]
  • [Cites] Head Neck. 1989 Mar-Apr;11(2):174-8 [2656583.001]
  • [Cites] Histopathology. 1990 May;16(5):487-93 [2361662.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):514-28 [2031528.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:263-304 [1736246.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2281-7 [8940996.001]
  • [Cites] Semin Diagn Pathol. 1997 Aug;14(3):203-12 [9279976.001]
  • [Cites] J Oral Pathol Med. 1998 May;27(5):225-8 [9682986.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):44-57 [17197918.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Laryngoscope. 2005 Jun;115(6):1097-100 [15933529.001]
  • [Cites] Head Neck. 2005 Aug;27(8):696-702 [16021638.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Mar;122(3):464 [10699832.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):823-30 [11764070.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):90-5 [11818141.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):676-85 [12033955.001]
  • [Cites] Int J Surg Pathol. 2005 Oct;13(4):329-35 [16273188.001]
  • (PMID = 20614263.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC2807526
  • [Keywords] NOTNLM ; Metastatic renal cell carcinoma / Oncocytic carcinoma / Oncocytoma / p63
  •  go-up   go-down


67. Hameed O, Sublett J, Humphrey PA: Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues. Am J Surg Pathol; 2005 May;29(5):579-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues.
  • The diagnosis of prostatic carcinoma and especially minimal prostatic carcinoma can sometimes be challenging on needle core biopsy and occasionally immunohistochemistry is an aid in the diagnosis.
  • Immunostains, such as those directed against the basal cell marker p63 and, more recently, employing antibodies reactive with alpha-methylacyl-CoA racemase (AMACR), can be useful in this situation.
  • A retrospective review of 31 consecutive radical prostatectomy specimens and 150 prostate needle biopsy samples was performed to select histologic sections showing foci of prostatic carcinoma and/or minimal prostatic carcinoma, high-grade prostatic intraepithelial neoplasia (HGPIN), as well as common benign mimickers of prostatic carcinoma, to include atrophy and basal cell hyperplasia, especially with prominent nucleoli.
  • These data indicate that use of a p63/AMACR cocktail is essentially equivalent to use of each antibody separately for immunohistochemical confirmation of a diagnosis of prostatic carcinoma in needle biopsy.
  • [MeSH-major] Adenocarcinoma / chemistry. Fluorescent Antibody Technique, Indirect. Membrane Proteins / analysis. Prostatic Intraepithelial Neoplasia / chemistry. Prostatic Neoplasms / chemistry. Racemases and Epimerases / analysis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy, Needle. Cell Nucleus / chemistry. Cell Nucleus / pathology. Humans. Male. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832080.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Clinical Conference; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


68. Paschoud S, Bongiovanni M, Pache JC, Citi S: Claudin-1 and claudin-5 expression patterns differentiate lung squamous cell carcinomas from adenocarcinomas. Mod Pathol; 2007 Sep;20(9):947-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-1 and claudin-5 expression patterns differentiate lung squamous cell carcinomas from adenocarcinomas.
  • We investigated the expression of tight junction proteins in human lung squamous cell carcinomas and adenocarcinomas by immunohistochemistry and quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR).
  • We found a statistically significant correlation between diagnosis and positivity of tumors with either claudin (CLDN)-1 or CLDN-5.
  • Squamous cell carcinomas and basal cells of bronchial epithelium were positive for CLDN-1 and negative for CLDN-5, whereas adenocarcinomas, normal cylindrical cells and pneumocytes were positive for CLDN-5 and negative for CLDN-1, suggesting different pathways in tumor development and progression.
  • CLDN-4 and ZO-1 staining were detected in both types of tumors, whereas cingulin (CGN) was not detected in squamous cell carcinomas.
  • In squamous cell carcinomas, we observed statistically significant decreases in the mRNA levels of JAM-1, occludin, CLDN-3, CLDN-4, CLDN-7, CGN, ZO-2 and ZO-3, and an increase in CLDN-1 mRNA.
  • In adenocarcinomas, when transcript levels were compared with bronchial cells, we observed statistically significant decreases in the mRNA levels of CLDN-1, CLDN-3, CLDN-4, CLDN-7, ZO-2 and ZO-3.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lung Neoplasms / diagnosis. Membrane Proteins / analysis. Tight Junctions / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Claudin-1. Claudin-4. Claudin-5. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Microfilament Proteins / analysis. Middle Aged. Neoplasm Staging. Phosphoproteins / analysis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Zonula Occludens-1 Protein

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585317.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CGN protein, human; 0 / CLDN1 protein, human; 0 / CLDN4 protein, human; 0 / CLDN5 protein, human; 0 / Claudin-1; 0 / Claudin-4; 0 / Claudin-5; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Phosphoproteins; 0 / RNA, Messenger; 0 / TJP1 protein, human; 0 / Zonula Occludens-1 Protein
  •  go-up   go-down


69. Lin HY, Cheng CY, Hsu WM, Kao WH, Chou P: Incidence of eyelid cancers in Taiwan: a 21-year review. Ophthalmology; 2006 Nov;113(11):2101-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We further examined the effects of age, period of diagnosis, and birth cohort on incidence trends using age-period-cohort analysis.
  • RESULTS: The mean age at diagnosis of eyelid cancers was 62.6+/-14.1 years.
  • The most common eyelid malignancy was basal cell carcinoma (BCC; 65.1%), followed by squamous cell carcinoma (12.6%), and sebaceous cell carcinoma (7.9%).
  • Basal cell carcinoma dominates the incidence trends, and the significant cohort effects give a warning of increasing risk of BCC in younger birth cohorts.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Eyelid Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma, Sebaceous / epidemiology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / epidemiology. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Registries. Retrospective Studies. Sebaceous Gland Neoplasms / epidemiology. Taiwan / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16962174.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Pereira PR, Odashiro AN, Rodrigues-Reyes AA, Correa ZM, de Souza Filho JP, Burnier MN Jr: Histopathological review of sebaceous carcinoma of the eyelid. J Cutan Pathol; 2005 Aug;32(7):496-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Sebaceous carcinoma of the eyelid can clinically mimic benign conditions, such as recurrent chalazion and inflammation and histopathologically squamous cell and basal cell carcinoma (BCC).
  • This retrospective study was undertaken as an attempt to improve the characterization and consequently the diagnosis of these tumors.
  • Of these, 75% had features similar to squamous cell carcinoma (SqCC), some with dyskeratosis (30%) and 7% resembled BCC.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Eyelid Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Chalazion / diagnosis. Diagnosis, Differential. Humans. Retrospective Studies. Single-Blind Method. Vacuoles / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008694.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


71. Cappello F, Di Stefano A, David S, Rappa F, Anzalone R, La Rocca G, D'Anna SE, Magno F, Donner CF, Balbi B, Zummo G: Hsp60 and Hsp10 down-regulation predicts bronchial epithelial carcinogenesis in smokers with chronic obstructive pulmonary disease. Cancer; 2006 Nov 15;107(10):2417-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A higher frequency of adenocarcinoma has been reported in patients with COPD.
  • Heat shock proteins (Hsps) are implicated in tumoral cell growth and differentiation.
  • METHOD: An immunohistochemical study was performed for Hsp60 and Hsp10 in bronchial biopsies from 35 COPD (postbronchodilator forced expiratory volume in 1 second [FEV(1)]: 53 +/- 19% [mean +/- SD]) patients with a history of smoking (53 +/- 34 pack/years) and in 10 patients with adenocarcinoma or adenosquamous carcinoma (ASC).
  • RESULTS.: In smokers with COPD, 10 out of 35 patients had a normal bronchial epithelium (NBE), 12 showed basal cell hyperplasia (BCH), 5 squamous metaplasia (SM), and 8 dysplasia (Dy).
  • [MeSH-major] Carcinoma, Bronchogenic / diagnosis. Chaperonin 10 / metabolism. Chaperonin 60 / metabolism. Lung Neoplasms / diagnosis. Pulmonary Disease, Chronic Obstructive / complications. Smoking / adverse effects
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Blotting, Western. Carcinoma, Adenosquamous / complications. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / pathology. Disease Progression. Down-Regulation. Humans. Middle Aged. Prognosis. Respiratory Mucosa / pathology


72. Lukáts O: [Oncological principles of surgery in the periorbital region]. Magy Onkol; 2005;49(1):47-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis in some of the cases is difficult, since the first signs of the tumours are small changes on the eyelid margin or eyelid skin.
  • Therefore, early diagnosis and total tumour removal--regardless of the anatomical borders--as well as immediate reconstruction are important in the treatment of eyelid tumours.
  • [MeSH-minor] Adenocarcinoma, Sebaceous / surgery. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Humans. Melanoma / surgery. Ophthalmologic Surgical Procedures / methods. Sebaceous Gland Neoplasms / surgery. Surgical Procedures, Operative / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902334.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 23
  •  go-up   go-down


73. Muthusamy K, Halbert G, Roberts F: Immunohistochemical staining for adipophilin, perilipin and TIP47. J Clin Pathol; 2006 Nov;59(11):1166-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The presence of lipid in the cell cytoplasm is useful for supporting the diagnosis of sebaceous gland carcinoma (SGC).
  • The immunostaining was compared with 22 other eyelid tumours (11 basal cell carcinomas (BCC), 10 squamous cell carcinomas (SCC) and 1 Merkel cell tumour).
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Biomarkers, Tumor / analysis. Eyelid Neoplasms / diagnosis. Lipids / analysis. Sebaceous Gland Neoplasms / diagnosis
  • [MeSH-minor] Adipocytes / immunology. Antibodies, Monoclonal / immunology. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Carrier Proteins. DNA-Binding Proteins / analysis. Diagnosis, Differential. Humans. Intracellular Signaling Peptides and Proteins / analysis. Membrane Proteins. Paraffin Embedding. Peptides / analysis. Phosphoproteins / analysis. Pregnancy Proteins / analysis. Vesicular Transport Proteins

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Dermatopathol. 1999 Oct;21(5):426-31 [10535570.001]
  • [Cites] Surv Ophthalmol. 2005 Mar-Apr;50(2):103-22 [15749305.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):5101-8 [11084026.001]
  • [Cites] Dermatol Surg. 2002 Jul;28(7):623-31 [12135523.001]
  • [Cites] Eye (Lond). 2004 Jan;18(1):49-53 [14707966.001]
  • [Cites] Am J Dermatopathol. 2004 Aug;26(4):298-303 [15249860.001]
  • [Cites] Dermatol Surg. 2004 Aug;30(8):1164-8 [15274713.001]
  • [Cites] Trans Am Acad Ophthalmol Otolaryngol. 1968 Jul-Aug;72(4):619-42 [5706692.001]
  • [Cites] Int Ophthalmol Clin. 1982 Spring;22(1):23-61 [7061198.001]
  • [Cites] Hum Pathol. 1982 Feb;13(2):113-22 [7076199.001]
  • [Cites] Arch Ophthalmol. 1984 Feb;102(2):245-9 [6696670.001]
  • [Cites] Surv Ophthalmol. 1989 May-Jun;33(6):477-90 [2658172.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1985;1(1):35-42 [3940100.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1991;7(1):61-6 [2018750.001]
  • [Cites] Histopathology. 1993 Feb;22(2):127-33 [7681028.001]
  • [Cites] J Am Acad Dermatol. 1995 Jul;33(1):1-15; quiz 16-8 [7601925.001]
  • [Cites] J Lipid Res. 1995 Jun;36(6):1211-26 [7665999.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1998 Aug;236(8):561-6 [9717649.001]
  • [Cites] Cell Tissue Res. 1998 Nov;294(2):309-21 [9799447.001]
  • [Cites] Br J Ophthalmol. 1998 Sep;82(9):1049-55 [9893597.001]
  • [Cites] Eye (Lond). 1999;13 ( Pt 1):104-8 [10396393.001]
  • [Cites] Ophthalmology. 2004 Dec;111(12):2151-7 [15582067.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1B):639-42 [11299819.001]
  • (PMID = 16556662.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Lipids; 0 / Membrane Proteins; 0 / PLIN3 protein, human; 0 / Peptides; 0 / Phosphoproteins; 0 / Pregnancy Proteins; 0 / Vesicular Transport Proteins; 0 / perilipin 1; 0 / perilipin 2
  • [Other-IDs] NLM/ PMC1860497
  •  go-up   go-down


74. Attlmayr B, Garrido C, Alderson DJ: Difficulty in establishing a diagnosis in an uncommon presentation of a minor salivary gland tumour. BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Difficulty in establishing a diagnosis in an uncommon presentation of a minor salivary gland tumour.
  • A firm diagnosis of malignancy could not be made histologically.
  • The differential diagnosis included polymorphous low-grade adenocarcinoma, basal cell adenoma and adenoid cystic carcinoma.
  • However, on balance, based on the clinical presentation, a diagnosis of malignancy was favoured and appropriate treatment was considered.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / pathology. Airway Obstruction / etiology. Deglutition Disorders / etiology. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy. Cooperative Behavior. Diagnosis, Differential. Endoscopy. Humans. Interdisciplinary Communication. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radiotherapy. Magnetic Resonance Imaging. Male. Middle Aged. Palliative Care. Tongue / pathology. Tracheostomy

  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Dis. 2002 Sep;8(5):229-40 [12363107.001]
  • [Cites] Am J Surg. 1991 Oct;162(4):330-6 [1659242.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):443-54 [8655366.001]
  • [Cites] Cancer Treat Rev. 1996 Nov;22(6):395-423 [9134002.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Apr;87(4):485-92 [10225632.001]
  • [Cites] Ann Surg. 1956 Sep;144(3):366-83 [13363274.001]
  • [Cites] Oral Oncol. 2008 Apr;44(4):407-17 [17825603.001]
  • (PMID = 22798299.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC3029651
  •  go-up   go-down


76. Humphrey PA: Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol; 2007 Jan;60(1):35-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of adenocarcinoma in prostate needle biopsy tissue.
  • For patients with clinically localised prostate cancer, the diagnosis is typically established by histopathological examination of prostate needle biopsy samples.
  • Major and minor criteria are used to establish the diagnosis, based on the microscopic appearance of slides stained using haematoxylin and eosin.
  • Major criteria include an infiltrative glandular growth pattern, an absence of basal cells and nuclear atypia in the form of nucleomegaly and nucleolomegaly.
  • In difficult cases, basal cell absence may be confirmed by immunohistochemical stains for high-molecular-weight cytokeratins (marked with antibody 34betaE12) or p63, which are basal cell markers.
  • Cocktails of antibodies directed against basal cell markers and AMACR are particularly useful in evaluating small foci of atypical glands, and in substantiating a diagnosis of a minimal adenocarcinoma.
  • Reporting of adenocarcinoma in needle biopsy specimens should always include the Gleason grade and measures of tumour extent in the needle core tissue.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Humans. Male. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):921-5 [12131160.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jan;124(1):98-107 [10629139.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1769-75 [11106548.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):794-801 [11395558.001]
  • [Cites] J Urol. 2001 Aug;166(2):402-10 [11458037.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1169-74 [12218573.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1588-96 [12459625.001]
  • [Cites] Prostate. 2003 Mar 1;54(4):290-8 [12539227.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):365-71 [12604893.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):432-40 [12657927.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):630-5 [12861057.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1128-33 [12883245.001]
  • [Cites] Prostate. 2003 Oct 1;57(2):93-8 [12949932.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):220-5 [14983935.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):328-48 [14976539.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):292-306 [14976540.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):701-5 [15166661.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):1008-13 [15297968.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):739-44 [15280928.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1224-9 [15316323.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1180-90 [15205683.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):517-23 [15487448.001]
  • [Cites] J Urol. 1980 May;123(5):686-8 [6158582.001]
  • [Cites] Am J Clin Pathol. 1983 Dec;80(6):850-4 [6195916.001]
  • [Cites] J Urol. 1986 Mar;135(3):507-9 [2418218.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):389-96 [2469333.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):820-34 [16469560.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):88-104 [16512601.001]
  • [Cites] Am J Clin Pathol. 1991 Mar;95(3):330-4 [1996542.001]
  • [Cites] Hum Pathol. 1993 Jun;24(6):618-23 [7684998.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):645-59 [7686348.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):819-32 [8375853.001]
  • [Cites] JAMA. 1994 Feb 2;271(5):368-74 [7506797.001]
  • [Cites] Arch Pathol Lab Med. 1994 Mar;118(3):260-4 [7510946.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):796-803 [8037294.001]
  • [Cites] Urology. 1994 Sep;44(3):371-6 [7521093.001]
  • [Cites] Hum Pathol. 1995 Feb;26(2):223-9 [7860053.001]
  • [Cites] Am J Surg Pathol. 1995 Mar;19(3):251-60 [7532918.001]
  • [Cites] Arch Pathol Lab Med. 1995 May;119(5):444-7 [7748073.001]
  • [Cites] Urology. 1995 Jun;45(6):981-6 [7539563.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):737-47 [7793471.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):419-26 [8604808.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):376-81 [8674022.001]
  • [Cites] Urology. 1997 Mar;49(3A Suppl):16-22 [9123731.001]
  • [Cites] Am J Surg Pathol. 1997 May;21(5):566-76 [9158682.001]
  • [Cites] Hum Pathol. 1998 May;29(5):543-6 [9596281.001]
  • [Cites] Mod Pathol. 1998 Jun;11(6):543-51 [9647592.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1073-7 [9737239.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):918-24 [10435561.001]
  • [Cites] AMA Arch Pathol. 1953 Feb;55(2):131-41 [13007281.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1462-8 [15619204.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):579-87 [15832080.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):231-6 [15842047.001]
  • [Cites] J Urol. 2005 Jul;174(1):121-5 [15947595.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):874-80 [15958851.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):20-33 [16019757.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1159-63 [16096404.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Am J Clin Pathol. 2005 Nov;124(5):708-15 [16203278.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):287-90 [16341144.001]
  • [Cites] Urology. 2001 Oct;58(4):619-24 [11597556.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Histopathology. 2002 Jul;41(1):35-41 [12121235.001]
  • (PMID = 17213347.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 74
  • [Other-IDs] NLM/ PMC1860598
  •  go-up   go-down


77. Heyl J, Mehregan D: Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas. J Cutan Pathol; 2008 Jan;35(1):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas.
  • BACKGROUND: Distinction between sebaceous tumors and basal cell carcinomas can often pose diagnostic problems.
  • Our aim was to evaluate the use of CK 19 staining patterns in differentiating between sebaceous tumors and basal cell carcinomas.
  • METHODS: Thirty-seven cases including 5 sebaceous adenomas, 16 sebaceous epitheliomas, 6 sebaceous carcinomas and 14 basal cell carcinomas (7 being of the morpheaform type and 7 nodular basal cell carcinomas) were tested with a monoclonal mouse antibody to human CK 19.
  • CK 19 was found to be strongly positive in 9/14 (64%) and focally positive in 2/14 (14%) of basal cell carcinomas.
  • CONCLUSION: CK 19 expression can be helpful in differentiating sebaceous tumors (including sebaceous adenomas, sebaceous epitheliomas and sebaceous carcinomas) from basal cell carcinomas and may be a useful adjunct when these entities are included in the differential diagnosis.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Adenoma / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / diagnosis. Keratin-19 / analysis. Sebaceous Gland Neoplasms / diagnosis. Sebaceous Glands / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Middle Aged

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095993.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-19
  •  go-up   go-down


78. Scholz N, Krugmann J, Scholtz A, Höllrigl A, Verdorfer I: Genetic alterations in a basal cell adenocarcinoma of the glandula submandibularis. Cancer Genet Cytogenet; 2007 Jan 1;172(1):87-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations in a basal cell adenocarcinoma of the glandula submandibularis.
  • [MeSH-major] Adenocarcinoma / genetics. Submandibular Gland Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175388.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


79. Montironi R, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M: Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. Nat Clin Pract Urol; 2007 Jun;4(6):321-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-grade prostatic intraepithelial neoplasia (HGPIN) is the most likely precursor of prostatic adenocarcinoma according to virtually all available evidence.
  • This lesion is characterized by cellular proliferations within pre-existing ducts and acini, with nuclear and nucleolar enlargements similar to those seen in prostate cancer, although unlike cancer HGPIN retains a basal-cell layer.
  • The predictive value for cancer of an initial diagnosis of HGPIN on needle biopsy has substantially declined, with values falling from 36% to 21%.
  • [MeSH-major] Precancerous Conditions. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Biopsy, Needle. Humans. Male. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551536.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 78
  •  go-up   go-down


80. Chetty R, Serra S, Hsieh E: Basaloid squamous carcinoma of the anal canal with an adenoid cystic pattern: histologic and immunohistochemical reappraisal of an unusual variant. Am J Surg Pathol; 2005 Dec;29(12):1668-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histologic differential diagnosis is true salivary gland-type adenoid cystic carcinoma and basal cell adenocarcinoma.
  • Immunohistochemistry and awareness of this unusual pattern of BSC will facilitate the correct diagnosis being reached.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Basosquamous / pathology
  • [MeSH-minor] Antibiotics, Antineoplastic / therapeutic use. Antigens, CD20 / metabolism. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cisplatin / therapeutic use. DNA-Binding Proteins. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Keratins / metabolism. Middle Aged. Mitomycin / therapeutic use. Phosphoproteins / metabolism. Radiotherapy. Time Factors. Trans-Activators / metabolism. Transcription Factors. Treatment Outcome. Tumor Burden. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327441.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antigens, CD20; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 50SG953SK6 / Mitomycin; 68238-35-7 / Keratins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


81. Wang W, Sun X, Epstein JI: Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study. Am J Surg Pathol; 2008 Jun;32(6):851-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study.
  • The morphologic features of the 278 cases and immunohistochemistry of 236 cases (198 with prostate cocktail and 38 with only basal cell makers) were analyzed.
  • Of 198 cases with a prostatic cocktail stain, 48 (24.2%) had a cancer pattern for both basal cells and AMACR (p63-, HMWCK-, and AMACR+), 14 (7.1%) had a cancer pattern for basal cells (p63-, HMWCK-, and AMACR-), 89 (44.9%) had a cancer pattern for AMACR (p63+, HMWCK+, and AMACR+), and 47 (23.7%) had a totally benign pattern (p63+, HMWCK+, and AMACR-).
  • Of the 198 cases using the cocktail stain, 136 (68.7%) had positive basal cell staining.
  • The percentage of basal cells labeled with the combination of p63/HMWCK was: <5% in 42 (21.2%) cases, 5% to 75% in 58 (29.3%) cases, and >75% in 36 (18.2%) cases.
  • In conclusion, partial atrophy is a benign mimicker of adenocarcinoma both as a result of its routine morphologic features and its immunohistochemical profile.
  • Recognition of the classic morphology of partial atrophy on routine hematoxylin and eosin-stained sections is critical to avoid misdiagnosing partial atrophy as adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Atrophy. Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18408595.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Markkanen-Leppänen M, Mäkitie AA, Passador-Santos F, Leivo I, Hagström J: Bilateral Basal cell adenocarcinoma of the parotid gland: in a recipient of kidney transplant. Clin Med Insights Pathol; 2010 Feb 18;3:1-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral Basal cell adenocarcinoma of the parotid gland: in a recipient of kidney transplant.
  • We report a rare case of bilateral basal cell adenocarcinoma (BcAC) of the parotid gland in a male patient 30 years after kidney transplantation and continuous administration of immunosuppressive therapy.
  • The most important differential diagnosis is basal cell adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151548.001).
  • [ISSN] 1179-5557
  • [Journal-full-title] Clinical medicine insights. Pathology
  • [ISO-abbreviation] Clin Med Insights Pathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2999998
  • [Keywords] NOTNLM ; basal cell adenocarcinoma / immunohistochemistry / post transplantation malignancy / salivary gland cancer
  •  go-up   go-down


83. Cheng L, Bostwick DG: Atypical sclerosing adenosis of the prostate: a rare mimic of adenocarcinoma. Histopathology; 2010 Apr;56(5):627-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical sclerosing adenosis of the prostate: a rare mimic of adenocarcinoma.
  • AIMS: Sclerosing adenosis of the prostate is a benign, small, acinar proliferation in dense spindle cell stroma, with a distinct immunohistochemical profiles.
  • METHODS AND RESULTS: We describe five cases of sclerosing adenosis with significant cytological atypia, referred to as atypical sclerosing adenosis (ASA), which were initially considered suspicious or diagnostic of adenocarcinoma.
  • All cases of typical and atypical sclerosing adenosis displayed an intact basal cell layer, which was immunoreactive for high-molecular-weight keratin, S100 protein, smooth muscle actin, and prostate-specific antigen, with no differences between ASA and the control group.
  • CONCLUSIONS: ASA is an unusual small, acinar proliferation of the prostate that may be mistaken for adenocarcinoma, and should be distinguished from other mimics, including atypical adenomatous hyperplasia, mesonephric remnant hyperplasia, and post-atrophic hyperplasia.
  • [MeSH-major] Adenocarcinoma / diagnosis. Prostatic Diseases / diagnosis. Prostatic Hyperplasia / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Biopsy, Needle. Diagnosis, Differential. Humans. Male. Middle Aged. Sclerosis

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459573.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


84. Begnami MD, Quezado M, Pinto P, Linehan WM, Merino M: Adenoid cystic/basal cell carcinoma of the prostate: review and update. Arch Pathol Lab Med; 2007 Apr;131(4):637-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic/basal cell carcinoma of the prostate: review and update.
  • Adenoid cystic/basal cell carcinoma of the prostate is a rare tumor with distinctive histopathologic features.
  • There are only a few publications in the literature concerning the diagnosis, treatment, and prognosis of this neoplasm.
  • OBJECTIVE: To review current literature together with the clinical, pathologic, and immunohistochemical features of adenoid cystic/basal cell carcinoma of the prostate and offer a practical approach to the diagnosis--including the differential diagnosis--of this neoplasm in surgical pathologic specimens.
  • DATA SOURCES: Adenoid cystic/basal cell carcinoma of the prostate is composed of infiltrating basaloid cells forming dilated acinar and cribriform spaces with luminal basementlike material.
  • Differentiation of adenoid cystic/basal cell carcinoma from basal cell hyperplasia and cribriform pattern of acinar adenocarcinoma may be difficult.
  • CONCLUSIONS: Various histologic and immunohistochemical features are helpful in recognizing adenoid cystic/basal cell carcinoma of the prostate.
  • This is a rare subtype of prostate cancer and correct diagnosis is important because of the unique clinical and biological features and the implications for treatment and prognosis.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Carcinoma, Basal Cell / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Male


85. Uphoff J, Woziwodzki J, Schattka SO, Kollias A: [Loss of differentiation of a prostate adenocarcinoma after hormone therapy: the example of a metastasis in the spongy body of the penis]. Aktuelle Urol; 2008 Sep;39(5):373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Loss of differentiation of a prostate adenocarcinoma after hormone therapy: the example of a metastasis in the spongy body of the penis].
  • Metastases in the penis only occur at an advanced state of the tumour and with a high dedifferentiation, e. g., ductal adenocarcinoma.
  • Changes in the morphology of the prostate carcinoma are specially known for the occurrence of small-cell neuroendocrine and undifferentiated carcinomas.
  • [MeSH-major] Adenocarcinoma / secondary. Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Basal Cell / secondary. Carcinoma, Transitional Cell / secondary. Cell Transformation, Neoplastic / pathology. Diphosphonates / therapeutic use. Gonadotropin-Releasing Hormone / antagonists & inhibitors. Neoplasms, Multiple Primary / drug therapy. Penile Neoplasms / secondary. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Biopsy. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Combined Modality Therapy. Cystectomy. Diagnosis, Differential. Disease Progression. Humans. Lymphatic Metastasis. Male. Neoplasm Staging. Penis / pathology. Penis / surgery. Prostate / pathology. Prostate / surgery. Prostatectomy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18798127.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Diphosphonates; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


86. Zheng J, Chen Y, Zhang J: [Basal cell adenocarcinoma of nasal septum: a case report and review of literatures]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Mar;23(5):209-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal cell adenocarcinoma of nasal septum: a case report and review of literatures].
  • OBJECTIVE: To summarize clinical features, diagnosis, differential diagnosis, treatment and prognosis of basal cell adenocarcinoma.
  • METHOD: A retrospective study were subjected to one case with basal cell adenocarcinoma of the nasal septum, and the related literature were reviewed.
  • RESULT: Basal cell adenocarcinoma often occurred in the salivary glands and minor salivary glands of salivary palate and other parts.
  • CONCLUSION: Basal cell adenocarcinoma is rare seen in the salivary gland tumors.
  • [MeSH-major] Adenocarcinoma. Nasal Septum / pathology. Nose Neoplasms

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522187.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


87. Hara H, Oyama T, Suda K: New criterial for cytologic diagnosis of adenoid cystic carcinoma. Acta Cytol; 2005 Jan-Feb;49(1):43-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New criterial for cytologic diagnosis of adenoid cystic carcinoma.
  • STUDY DESIGN: The usefulness of 17 items for a cytologically definitive diagnosis of ADCC was examined.
  • The frequency (- - +++) of the 17 items in 18 cases of ADCC and 10 non-ADCC cases (pleomorphic adenoma, basal cell adenoma, myoepithelioma and epithelial-myoepithelial carcinoma) that displayed mimicking cytology was examined cytologically.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / pathology. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenoma / diagnosis. Adenoma / pathology. Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / pathology. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Myoepithelioma / diagnosis. Myoepithelioma / pathology. Staining and Labeling

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15717754.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


88. Netto GJ, Epstein JI: Benign Mimickers of Prostate Adenocarcinoma on Needle Biopsy and Transurethral Resection. Surg Pathol Clin; 2008 Dec;1(1):1-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign Mimickers of Prostate Adenocarcinoma on Needle Biopsy and Transurethral Resection.
  • Prostate needle biopsy currently is the gold standard method for the diagnosis, management, and prognosis of prostate cancer.
  • Obtaining an accurate diagnosis is crucial for pursuing proper patient management.
  • This article discusses histologic mimickers of prostate carcinoma highlighting microscopic features that are helpful to reach a correct diagnosis and emphasizing potential diagnostic pitfalls.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Elsevier Inc. All rights reserved.
  • (PMID = 26837901.001).
  • [ISSN] 1875-9181
  • [Journal-full-title] Surgical pathology clinics
  • [ISO-abbreviation] Surg Pathol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Adenosis / Atrophy / Basal cell hyperplasia / Clear cell cribriform hyperplasia / Mimickers of prostate cancer / Nephrogenic adenoma / Paraganglia / Prostatitis / Radiation atypia / Xanthoma
  •  go-up   go-down


89. Bonkhoff H: [Differential diagnosis of prostate cancer: impact of pattern analysis and immunohistochemistry]. Pathologe; 2005 Nov;26(6):405-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential diagnosis of prostate cancer: impact of pattern analysis and immunohistochemistry].
  • For each Gleason pattern exist a number of benign and malignant mimickers that can simulate prostatic adenocarcinoma.
  • In the present review, the use of immunohistochemical markers is discussed with emphasis to a pattern-based approach to differential diagnosis in prostate pathology.
  • Basal cell markers (34betaE12 and P63) are very useful to analyze histo-architectural features of small and large glandular lesions.
  • AMACR (P504 s) is helpful not only in identifying small amount of cancer in needle biopsies but also in the diagnosis of high grade prostatic intra epithelial neoplasia (HGPIN).
  • A number of lesions which may be confused with small acinar adenocarcinoma (Cowper's gland, nephrogenic metaplasia, mesonephric glands) and poorly differentiated prostate cancer (urothelial neoplasia, mucinous colon cancer and other metastatic lesions) lacks convincing PSA immunoreactivity.
  • Basal cell markers and the nuclear androgen receptors are important markers to differentiate Gleason grade 5 A und 5 B patterns from prostatic involvement by transitional cell carcinoma.
  • [MeSH-minor] Carcinoma, Basal Cell / pathology. Cell Division / physiology. Diagnosis, Differential. Humans. Male. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / pathology


90. Andreadis D, Epivatianos A, Poulopoulos A, Nomikos A, Papazoglou G, Antoniades D, Barbatis C: Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncol; 2006 Jan;42(1):57-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • C-KIT expression was observed in cases of adenoid cystic, acinic cell polymorphous low grade, epithelial-myoepithelial, carcinosarcoma and basal cell adenocarcinomas, as in luminal cells of pleomorphic adenomas, in serous acinar and only in intercalated and a small number of striated ductal cells of inflammatory salivary gland tissue, whereas normal salivary lobules were generally negative except a weak positivity of intercalated cells.
  • Contrary to other reports, this study suggests that, C-KIT protein does not appear to be an exclusively specific marker for benign or malignant salivary gland neoplasms, but may be useful in differential diagnosis of adenoid cystic carcinoma from polymorphous low grade adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140564.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


91. Dhillon PK, Barry M, Stampfer MJ, Perner S, Fiorentino M, Fornari A, Ma J, Fleet J, Kurth T, Rubin MA, Mucci LA: Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev; 2009 Feb;18(2):595-600
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We correlated p63 expression with tumor cell proliferation (Ki-67) and apoptosis (TUNEL staining).
  • The predominant location of tumor p63 staining occurred in the cytoplasm, an uncommon departure from the strong nuclear staining usually observed in nonneoplastic basal cells.
  • The positive trend remained significant (P = 0.047) after multivariable adjustment for age, year of diagnosis, and Gleason score.
  • We found aberrant expression of p63 in the cytoplasm to be associated with increased prostate cancer-specific mortality up to 20 years after diagnosis.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1424-32 [15941951.001]
  • [Cites] Hum Pathol. 2005 Feb;36(2):187-94 [15754296.001]
  • [Cites] BMC Bioinformatics. 2005;6:304 [16364175.001]
  • [Cites] Neoplasia. 2006 Jan;8(1):59-68 [16533427.001]
  • [Cites] BJU Int. 2006 May;97(5):1109-15 [16643500.001]
  • [Cites] Histopathology. 2006 Oct;49(4):349-57 [16978197.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):300-4 [17264676.001]
  • [Cites] Oncogene. 2007 Apr 2;26(15):2220-5 [17401431.001]
  • [Cites] J Biol Chem. 2007 May 11;282(19):14616-25 [17371868.001]
  • [Cites] Ann Oncol. 2008 Mar;19(3):501-7 [17998283.001]
  • [Cites] Am J Surg Pathol. 2008 Mar;32(3):461-7 [18300803.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1682-8 [18583469.001]
  • [Cites] Ann Epidemiol. 2000 Feb;10(2):125-34 [10691066.001]
  • [Cites] Nat Cell Biol. 2000 Sep;2(9):569-73 [10980696.001]
  • [Cites] Biochim Biophys Acta. 2000 Jul 31;1471(1):M31-41 [10967423.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1769-75 [11106548.001]
  • [Cites] DNA Cell Biol. 2001 Jun;20(6):321-30 [11445003.001]
  • [Cites] Urology. 2001 Oct;58(4):619-24 [11597556.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45255-60 [11572869.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):312-9 [11859202.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):15053-60 [11847229.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1151-60 [12218571.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1161-8 [12218572.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1199-206 [12368193.001]
  • [Cites] Exp Cell Res. 2003 Jan 15;282(2):59-69 [12531692.001]
  • [Cites] Urology. 2004 Jun;63(6):1079-83 [15183954.001]
  • [Cites] N Engl J Med. 1989 Jul 20;321(3):129-35 [2664509.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7262-6 [1353891.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;423(6):443-8 [8291217.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):790-8 [7677190.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):1126-37 [8622657.001]
  • [Cites] Nature. 1997 May 15;387(6630):296-9 [9153395.001]
  • [Cites] EMBO J. 1998 Jan 15;17(2):554-64 [9430646.001]
  • [Cites] Nat Med. 1998 Jul;4(7):747-8 [9662346.001]
  • [Cites] Urology. 1998 Oct;52(4):594-601 [9763077.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1763-8 [9802988.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3077-80 [10077639.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Oncogene. 1999 Aug 12;18(32):4606-15 [10467405.001]
  • [Cites] Genes Dev. 2005 Sep 1;19(17):1986-99 [16107615.001]
  • (PMID = 19155438.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-40360; United States / NCI NIH HHS / CA / CA-34944; United States / NCI NIH HHS / CA / R01 CA040360-17; United States / NHLBI NIH HHS / HL / HL-34595; United States / NHLBI NIH HHS / HL / HL-26490; United States / NCI NIH HHS / CA / T32 CA009001-33; United States / NCI NIH HHS / CA / R01 CA090598; United States / NCI NIH HHS / CA / R01 CA097193-07; United States / NHLBI NIH HHS / HL / R01 HL034595; United States / NCI NIH HHS / CA / CA009001-33; United States / NCI NIH HHS / CA / CA097193-07; United States / NCI NIH HHS / CA / R01 CA034944-03; United States / NCI NIH HHS / CA / R01 CA090598-05; United States / NHLBI NIH HHS / HL / R01 HL026490; United States / NCI NIH HHS / CA / CA090598-05; United States / NCI NIH HHS / CA / T32 CA009001; United States / NHLBI NIH HHS / HL / R01 HL034595-07; United States / NCI NIH HHS / CA / CA-097193; United States / NCI NIH HHS / CA / R01 CA040360; United States / NHLBI NIH HHS / HL / R01 HL026490-03; United States / NCI NIH HHS / CA / R01 CA097193; United States / NCI NIH HHS / CA / R01 CA034944; United States / NCI NIH HHS / CA / 5R01 CA090598
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Ki-67 Antigen; 0 / Membrane Proteins
  • [Other-IDs] NLM/ NIHMS107808; NLM/ PMC2692093
  •  go-up   go-down


92. Gupta G, Singh R, Shanmugasamy K, Kotasthane DS, Kotasthane VD: Basal cell adenocarcinoma in the tongue: an unusual presentation. Clin Med Insights Oncol; 2010 Nov 21;4:127-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma in the tongue: an unusual presentation.
  • We present a case of basal cell adenocarcinoma (BCAC) in the tongue in a 65-year old male.
  • The clinicopathological features and the cellular immunophenotype addressed the diagnosis towards BCAC of the tongue.
  • The goal of this report is to increase awareness of this rare disease and to review and discuss the differential diagnosis and important considerations in treatment.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151583.001).
  • [ISSN] 1179-5549
  • [Journal-full-title] Clinical Medicine Insights. Oncology
  • [ISO-abbreviation] Clin Med Insights Oncol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2999957
  • [Keywords] NOTNLM ; basal cell adenocarcinoma / minor salivary gland / tongue
  •  go-up   go-down


93. Chen CH, Rowlands C, Sengupta SK, George RL, Parulekar W, Thain K, O'Malley F, Isotalo PA: Primary basaloid carcinoma of the nipple with associated squamous cell carcinoma in situ. Breast J; 2009 Jul-Aug;15(4):409-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary basaloid carcinoma of the nipple with associated squamous cell carcinoma in situ.
  • We describe a primary invasive adenocarcinoma of the nipple with extensive basaloid features that was also associated with squamous cell carcinoma (SCC) in situ and an aggressive behavior.
  • The differential diagnosis included a primary basaloid adenocarcinoma of the nipple, basal cell carcinoma of the nipple, neuroendocrine carcinoma, melanoma, basaloid variant of adenoid cystic carcinoma and metastatic disease.
  • Immunohistochemical profile of this tumor supported a primary basaloid adenocarcinoma of the nipple.
  • Although the initial sentinel lymph node biopsy was negative, within a year of diagnosis, the patient developed ipsilateral axillary node and pulmonary metastases.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Nipples / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19601946.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


94. Jingu K, Hasegawa A, Mizo JE, Bessho H, Morikawa T, Tsuji H, Tsujii H, Kamada T: Carbon ion radiotherapy for basal cell adenocarcinoma of the head and neck: preliminary report of six cases and review of the literature. Radiat Oncol; 2010;5:89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbon ion radiotherapy for basal cell adenocarcinoma of the head and neck: preliminary report of six cases and review of the literature.
  • BACKGROUND: Basal cell adenocarcinoma accounts for approximately 1.6% of all salivary gland neoplasms.
  • METHODS: Case records of 6 patients with diagnosis of basal cell adenocarcinoma of the head and neck, who were treated by carbon ion radiotherapy with 64.0 GyE/16 fractions in our institution, were retrospectively reviewed.
  • CONCLUSIONS: Carbon ion radiotherapy should be considered as an appropriate curative approach for treatment of basal cell adenocarcinoma in certain cases, particularly in cases of unresectable disease and postoperative gross residual or recurrent disease.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carbon / therapeutic use. Head and Neck Neoplasms / radiotherapy. Heavy Ions / therapeutic use

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):737-43 [11020570.001]
  • [Cites] Histopathology. 2003 Jun;42(6):610-4 [12786899.001]
  • [Cites] Arch Otolaryngol. 1978 Feb;104(2):111-6 [629699.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Apr;69(4):461-9 [2326038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Am J Clin Oncol. 1992 Oct;15(5):441-5 [1326226.001]
  • [Cites] Cancer. 1996 Dec 15;78(12):2471-7 [8952553.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):439-47 [9452259.001]
  • [Cites] HNO. 1998 Sep;46(9):821-5 [9816537.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):201-10 [10219815.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):71-82 [15915466.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):396-401 [16182466.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 Mar;11(2):E206-9 [16505803.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jan;103(1):77-84 [17178498.001]
  • (PMID = 20920325.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 7440-44-0 / Carbon
  • [Other-IDs] NLM/ PMC2958970
  •  go-up   go-down


95. Pozharisskiĭ KM, Leenman EE, Arzumanov AA: [Achievements in morphological diagnosis of prostatic cancer: alpha-methylacyl-coenzyme-A-racemase--a new marker of malignant cell transformation]. Arkh Patol; 2005 Sep-Oct;67(5):15-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Achievements in morphological diagnosis of prostatic cancer: alpha-methylacyl-coenzyme-A-racemase--a new marker of malignant cell transformation].
  • Gene P504S is considered as the most specific for prostatic carcinoma and its protein (alpha-methylacyl coenzyme A racemaze (AMACR/P504S) is higly sensitive and specific marker not only for adenocarcinoma cells but also for preceding changes - prostatic intraepithelial neoplasm (PIN).
  • Use of immunohistochemical method for revealing this marker together with methods of basal prostatic cells observation (cytokeratin of a high molecular weight, cytokeratin 5/6, p63) improves morphological diagnosis of prostatic carcinoma, particularly on the material of needle biopsies.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Neoplasms / diagnosis. Racemases and Epimerases / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323473.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] Editorial; English Abstract
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


96. Sramek B, Lisle A, Loy T: Immunohistochemistry in ocular carcinomas. J Cutan Pathol; 2008 Jul;35(7):641-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The distinction between ocular sebaceous carcinoma, poorly differentiated ocular squamous cell carcinoma and ocular basal cell carcinoma can be challenging.
  • RESULTS: Positive staining for cytokeratin (CK)7 was seen in 100% of sebaceous carcinomas, 77.8% of basal cell carcinomas and 67.7% of squamous cell carcinomas.
  • One hundred percent of sebaceous and basal cell carcinomas were positive for cytokeratin CAM 5.2, while only 83.3% of squamous cell carcinomas were positive.
  • Using epithelial membrane antigen (EMA), 100% of squamous cell carcinomas and 80% of sebaceous carcinomas were positive, while basal cell carcinomas were uniformly negative.
  • One hundred percent of basal cell carcinomas and 80% of sebaceous carcinomas were positive for Ber-EP4, while all squamous cell carcinomas were negative.
  • Finally, 77.8%, 20% and 16.7% of basal cell carcinomas, sebaceous carcinomas and squamous cell carcinomas showed immunoreactivity for the androgen receptor.
  • CONCLUSION: An EMA positive, Ber-EP4 positive immunophenotype supports sebaceous carcinoma, EMA positive, Ber-EP4 negative result supports squamous cell carcinoma and an EMA negative, Ber-EP4 positive result supports basal cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Eye Neoplasms / pathology. Sebaceous Gland Neoplasms / pathology. Skin / pathology
  • [MeSH-minor] Biomarkers / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Keratin-7 / metabolism. Keratins / metabolism. Mucin-1 / metabolism. Receptors, Androgen / metabolism

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18201230.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / CAM 5.2 antigen; 0 / Keratin-7; 0 / Mucin-1; 0 / Receptors, Androgen; 0 / human epithelial antigen-125; 68238-35-7 / Keratins
  •  go-up   go-down


97. Marci V, Volante M, Cappia S, Righi L, Novello C, Scagliotti GV, Brambilla E, Papotti M: Basaloid adenocarcinoma. A new variant of pulmonary adenocarcinoma. Virchows Arch; 2007 Sep;451(3):729-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid adenocarcinoma. A new variant of pulmonary adenocarcinoma.
  • The 2004 WHO classification of lung tumours recognised basaloid carcinoma as a variant of squamous and large cell carcinoma.
  • We report a unique case of primary pulmonary adenocarcinoma with a basaloid component.
  • The patient is disease-free 13 months after diagnosis.
  • The former was an adenocarcinoma with mucus containing spaces lined by columnar mucinous cells and basaloid cells.
  • The solid component was an organoid proliferation of basaloid-type cells, as in cutaneous basal cell carcinoma.
  • (1) The solid areas resemble a conventional basaloid carcinoma, except for the presence of small mucin-containing spaces. (2) The mucinous adenocarcinoma areas contain two layers of columnar and basaloid cells. (3) Both components are neoplastic based on cell morphology, invasive properties and phenotypic profile.
  • These findings indicate that a basaloid variant of adenocarcinoma is also existing in the spectrum of basaloid carcinomas of the lung.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Carcinoma, Basal Cell. Humans. Keratins / analysis. Male. Mucins / analysis. Neoplasm Invasiveness. Phenotype. World Health Organization


98. Lynch MC, Anderson BE: Ileocecal adenocarcinoma and ureteral transitional cell carcinoma with multiple sebaceous tumors and keratoacanthomas in a case of muir-torre syndrome. Dermatol Res Pract; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ileocecal adenocarcinoma and ureteral transitional cell carcinoma with multiple sebaceous tumors and keratoacanthomas in a case of muir-torre syndrome.
  • Cutaneous neoplasms including sebaceous tumors, keratoacanthomas, and basal cell carcinomas with sebaceous differentiation can be markers of internal malignancy associated with the Muir-Torre Syndrome (MTS).
  • We report a 56-year-old man with a diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) and ureteral transitional cell carcinoma who subsequently developed two sebaceous gland neoplasms and several keratoacanthomas, leading to the diagnosis of MTS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20814549.001).
  • [ISSN] 1687-6113
  • [Journal-full-title] Dermatology research and practice
  • [ISO-abbreviation] Dermatol Res Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2931389
  •  go-up   go-down


99. Garcia MT, Acar BC, Jorda M, Gomez-Fernandez C, Ganjei-Azar P: Use of p63 for distinction of glandular versus squamous lesions in cervicovaginal specimens. Cancer; 2007 Feb 25;111(1):54-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous and atypical glandular cell lesions may show similar cytomorphologic features.
  • The aim of this study was to evaluate the use of p63 as a marker of basal and/or squamous cell derivation in this differential diagnosis.
  • METHODS: Of 59,257 liquid-based cervicovaginal specimens collected over a 3-year period, 149 were diagnosed as atypical glandular cells of uncertain significance (AGUS) or adenocarcinoma and had histological follow-up.
  • Ten cases (8AGUS and 2 adenocarcinomas) were proven to be high-grade dysplasia on cervical biopsies and the remaining cases represented glandular pathology.
  • In addition, the authors stained 25 control cases (10 adenocarcinomas, 10 HSIL, and 5 negative cervicovaginal specimens).
  • Nuclei of isolated HSIL cells and basal cells from atrophic smears were also positive for p63.
  • This antibody is not expressed in AGUS, adenocarcinoma, or normal glandular cells. p63 stains basal cells and may be a diagnostic pitfall in atrophic cervicovaginal specimens.
  • [MeSH-major] Membrane Proteins / metabolism. Neoplasms, Glandular and Epithelial / diagnosis. Neoplasms, Squamous Cell / diagnosis. Uterine Cervical Neoplasms / diagnosis. Vaginal Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / immunology. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods


100. Hameed O, Humphrey PA: Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia. Mod Pathol; 2006 Jul;19(7):899-906
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia.
  • Typically glands of prostatic adenocarcinoma have a single cell lining, although stratification can be seen in invasive carcinomas with a cribriform architecture, including ductal carcinoma.
  • The histomorphological features and immunohistochemical profile of cases of non-cribriform prostatic adenocarcinoma with stratified malignant glandular epithelium were analyzed.
  • These cases were identified from needle biopsy cases from the consultation files of one of the authors and from a review of 150 consecutive in-house needle biopsy cases of prostatic adenocarcinoma.
  • The main attribute in all these foci was the presence of glandular profiles lined by several layers of epithelial cells with cytological and architectural features resembling flat or tufted high-grade prostatic intraepithelial neoplasia, but lacking basal cells as confirmed by negative 34betaE12 and/or p63 immunostains in all cases.
  • The AMACR staining profile of the stratified foci was variable, with 4 foci showing positivity, and 3 foci being negative, including two cases that displayed AMACR positivity in adjacent non-stratified prostatic adenocarcinoma.
  • Prostatic adenocarcinoma with stratified malignant glandular epithelium can be identified in prostate needle biopsy samples harboring non-cribriform prostatic adenocarcinoma and resembles glands with high-grade prostatic intraepithelial neoplasia.
  • Recognition of this pattern of prostatic adenocarcinoma is necessary to correctly diagnose such cases as invasive carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Epithelium / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. Male. Membrane Proteins / metabolism. Middle Aged. Neoplasm Invasiveness. Prostate-Specific Antigen / blood. Racemases and Epimerases / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607376.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins; EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down






Advertisement